prednisolone has been researched along with Diffuse Large B-Cell Lymphoma in 363 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL)." | 9.69 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving S ( Bae, SH; Choi, CW; Eom, HS; Kang, HJ; Kim, HJ; Kim, JS; Kim, MK; Kim, WS; Kim, YR; Kwak, JY; Lee, JH; Mun, YC; Nam, SH; Oh, SJ; Oh, SY; Park, JS; Shim, H; Suh, C; Yang, DH; Yoon, SS, 2023) |
| "The clinical efficacy and safety of yttrium-90 ((90)Y)-ibritumomab tiuxetan consolidation treatment following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy was investigated in patients with limited-stage and bulky diffuse large B-cell lymphoma (DLBCL)." | 9.16 | Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. ( Chung, JS; Kim, JS; Kim, SJ; Kim, WS; Kwak, JY; Lee, JJ; Oh, SY; Suh, C; Yang, DH, 2012) |
| " We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 9.15 | Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. ( Fukuno, K; Goto, H; Goto, N; Hara, T; Kanemura, N; Kasahara, S; Kitagawa, J; Moriwaki, H; Sawada, M; Takahashi, T; Takami, T; Tsurumi, H; Yamada, T; Yoshikawa, T, 2011) |
| " We describe a rare case of multiple organ failure due to intravascular lymphoma with severe lactic acidosis in a patient who survived." | 7.96 | Successful Intensive Care Treatment of Severe Lactic Acidosis and Tumor Lysis Syndrome Related to Intravascular Lymphoma. ( Genda, Y; Ichiba, S; Mase, H; Ogawa, Y; Sakamoto, A; Takeuchi, J, 2020) |
| "No randomised study in the rituximab era has been performed specifically to evaluate addition of etoposide to treatment of diffuse large B-cell lymphoma (DLBCL)." | 7.85 | Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. ( Hartman, L; Jerkeman, M; Székely, E; Wästerlid, T, 2017) |
| "Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is regarded as the first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), but it is often necessary to reduce the dose or prolong the intervals between doses." | 7.79 | Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. ( Aoki, K; Ishikawa, T; Kurata, M; Matsushita, A; Nagai, K; Tabata, S; Takahashi, T, 2013) |
| " We present the results of systemic treatment using rituximab plus dose reduced mitoxantrone, cyclophosphamide, vincristine, and prednisolone in three elderly patients with primary diffuse large B-cell lymphoma (DLBCL) of the thyroid." | 7.76 | Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid. ( Hoffmann, M; Jonak, C; Müllauer, L; Niederle, B; Raderer, M; Troch, M, 2010) |
| "We report a patient with rheumatoid arthritis (RA) who developed malignant lymphoma of the diffuse large B-cell type in the right submandibular region shortly after initiation of oral methotrexate (MTX)." | 7.72 | Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate. ( Gono, T; Hoshi, K; Ikeda, S; Matsuda, M; Shikama, N; Shimojima, Y; Tokuda, T; Yamamoto, K, 2004) |
| "Management of acquired immunodeficiency syndrome (AIDS)-related diffuse large B-cell (DLBCL) and plasmablastic lymphomas (PBL) poses significant challenges." | 7.30 | Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. ( Agarwal, A; Alahari, A; Bagal, B; Gota, V; Gujral, S; Gupta, H; Jain, H; Kannan, S; Kumar, S; Laskar, SS; Menon, H; Nayak, L; Rangarajan, V; Sengar, M; Sharma, N; Shet, T; Sridhar, E; Thorat, J, 2023) |
| "The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established." | 6.80 | Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015) |
| "Tacrolimus was discontinued." | 6.48 | Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. ( Imai, H; Komatsu, N; Nakamura, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Wakabayashi, M, 2012) |
| "This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL)." | 5.69 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving S ( Bae, SH; Choi, CW; Eom, HS; Kang, HJ; Kim, HJ; Kim, JS; Kim, MK; Kim, WS; Kim, YR; Kwak, JY; Lee, JH; Mun, YC; Nam, SH; Oh, SJ; Oh, SY; Park, JS; Shim, H; Suh, C; Yang, DH; Yoon, SS, 2023) |
| "Chemoimmunotherapy containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is the standard treatment for diffuse large B-cell lymphoma (DLBCL)." | 5.22 | Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B- ( Andel, J; Burgstaller, S; Fridrik, MA; Greil, R; Jaeger, U; Keil, F; Krieger, O; Lang, A; Oberaigner, W; Petzer, A; Sihorsch, K; Willenbacher, W, 2016) |
| "Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8)." | 5.22 | Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. ( Friedberg, JW; LeBlanc, ML; Li, H; Persky, D; Puvvada, SD; Smith, SM; Stephens, DM, 2016) |
| "To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) compared with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP)." | 5.19 | Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho ( Berger, F; Brière, J; Canioni, D; Casasnovas, O; Coiffier, B; Copie-Bergman, C; Copin, MC; Fabiani, B; Fermé, C; Gaulard, P; Haioun, C; Jais, JP; Jardin, F; Leroy, K; Molina, TJ; Morschauser, F; Mounier, N; Petrella, T; Recher, C; Salles, G; Thieblemont, C; Tilly, H, 2014) |
| "The aim of this study was to evaluate the efficacy and toxicity of reduced-dose (RD) RCHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy for elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 5.16 | Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. ( Cho, GJ; Choe, S; Chung, JS; Kim, SK; Shin, HJ; Song, MK, 2012) |
| "The clinical efficacy and safety of yttrium-90 ((90)Y)-ibritumomab tiuxetan consolidation treatment following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy was investigated in patients with limited-stage and bulky diffuse large B-cell lymphoma (DLBCL)." | 5.16 | Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. ( Chung, JS; Kim, JS; Kim, SJ; Kim, WS; Kwak, JY; Lee, JJ; Oh, SY; Suh, C; Yang, DH, 2012) |
| " We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 5.15 | Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. ( Fukuno, K; Goto, H; Goto, N; Hara, T; Kanemura, N; Kasahara, S; Kitagawa, J; Moriwaki, H; Sawada, M; Takahashi, T; Takami, T; Tsurumi, H; Yamada, T; Yoshikawa, T, 2011) |
| "We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL)." | 5.14 | Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. ( Fukuno, K; Goto, H; Goto, N; Hara, T; Kanemura, N; Kasahara, S; Katsumura, N; Kitagawa, J; Moriwaki, H; Sawada, M; Takahashi, T; Takami, T; Tsurumi, H; Yamada, T; Yasuda, I; Yoshikawa, T, 2010) |
| " Association of rituximab with chemotherapy (mostly the cyclophosphamide, doxorubicin, vincristine and prednisolone [CHOP] regimen) in diffuse large B-cell lymphoma (DLBCL) represents an extraordinary revolution in the prognosis of DLBCL, and is the new standard of therapy in elderly and young, low-risk patients." | 4.85 | Rituximab and chemotherapy in diffuse large B-cell lymphoma. ( Bosly, A; Sonet, A, 2009) |
| "To determine the clinical and cost-effectiveness of adding rituximab to the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regime for adult patients with diffuse large B-cell lymphoma (DLBCL)." | 4.82 | Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. ( Abbott, V; Brewer, N; Hind, D; Knight, C, 2004) |
| "Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP)." | 4.12 | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. ( Choi, YS; Do, YR; Eom, HS; Hyun, SY; Jeong, SH; Jo, JC; Kang, HJ; Kim, HJ; Kim, MK; Kim, SH; Kim, SJ; Kim, WS; Koh, Y; Kwak, JY; Kwon, JH; Lee, GW; Lee, HS; Lee, WS; Oh, SY; Park, BB; Park, Y; Shin, HJ; Sohn, BS; Suh, C; Won, JH; Yang, DH; Yi, JH; Yi, SY; Yoo, KH; Yoon, DH; Yun, HJ, 2022) |
| " We describe a rare case of multiple organ failure due to intravascular lymphoma with severe lactic acidosis in a patient who survived." | 3.96 | Successful Intensive Care Treatment of Severe Lactic Acidosis and Tumor Lysis Syndrome Related to Intravascular Lymphoma. ( Genda, Y; Ichiba, S; Mase, H; Ogawa, Y; Sakamoto, A; Takeuchi, J, 2020) |
| "No randomised study in the rituximab era has been performed specifically to evaluate addition of etoposide to treatment of diffuse large B-cell lymphoma (DLBCL)." | 3.85 | Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. ( Hartman, L; Jerkeman, M; Székely, E; Wästerlid, T, 2017) |
| "Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled." | 3.81 | Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas. ( Choi, CW; Gang, GW; Kim, BS; Kim, DS; Kim, JS; Lee, SR; Park, Y; Sung, HJ, 2015) |
| "Chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab (R-CHOP) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL)." | 3.80 | R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma. ( Augustin, D; Baldus, CD; Kreher, S; Lammer, F; Pezzutto, A, 2014) |
| "Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is regarded as the first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), but it is often necessary to reduce the dose or prolong the intervals between doses." | 3.79 | Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. ( Aoki, K; Ishikawa, T; Kurata, M; Matsushita, A; Nagai, K; Tabata, S; Takahashi, T, 2013) |
| "The prognosis of diffuse large B-cell lymphoma (DLBCL) has improved significantly since the introduction of immunochemotherapy (rituximab [R] with cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP])." | 3.78 | Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. ( Andersson, PO; Hansson, U; Hasselblom, S; Lewerin, C; Nilsson-Ehle, H; Sender, M; Stenson, M; Werlenius, O, 2012) |
| " We present the results of systemic treatment using rituximab plus dose reduced mitoxantrone, cyclophosphamide, vincristine, and prednisolone in three elderly patients with primary diffuse large B-cell lymphoma (DLBCL) of the thyroid." | 3.76 | Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid. ( Hoffmann, M; Jonak, C; Müllauer, L; Niederle, B; Raderer, M; Troch, M, 2010) |
| "The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N=30), or <5 years of remission (early relapse, N=132), were compared." | 3.76 | Late relapse in patients with diffuse large B-cell lymphoma. ( Arevalo, A; Armitage, J; Armitage, JO; Bast, M; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; Weisenburger, DD, 2010) |
| "We report a patient with rheumatoid arthritis (RA) who developed malignant lymphoma of the diffuse large B-cell type in the right submandibular region shortly after initiation of oral methotrexate (MTX)." | 3.72 | Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate. ( Gono, T; Hoshi, K; Ikeda, S; Matsuda, M; Shikama, N; Shimojima, Y; Tokuda, T; Yamamoto, K, 2004) |
| "Management of acquired immunodeficiency syndrome (AIDS)-related diffuse large B-cell (DLBCL) and plasmablastic lymphomas (PBL) poses significant challenges." | 3.30 | Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. ( Agarwal, A; Alahari, A; Bagal, B; Gota, V; Gujral, S; Gupta, H; Jain, H; Kannan, S; Kumar, S; Laskar, SS; Menon, H; Nayak, L; Rangarajan, V; Sengar, M; Sharma, N; Shet, T; Sridhar, E; Thorat, J, 2023) |
| "The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established." | 2.80 | Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015) |
| "Sarcopenia was measured by the analysis of CT images at the L3 level before treatment." | 2.80 | Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. ( Goto, N; Hara, T; Kanemura, N; Kitagawa, J; Kito, Y; Matsumoto, T; Miyazaki, T; Nakamura, H; Nakamura, N; Ninomiya, S; Shibata, Y; Shimizu, M; Shiraki, M; Takeuchi, T; Tsurumi, H, 2015) |
| " Our study suggests that the MTD of idarubicin in combination with HD-MTX, VDS, and PRED, should be 16 mg/m(2) ." | 2.79 | A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. ( Brion, A; Chabin, M; Clavert, A; Colombat, P; Cumin, I; Delwail, V; Escoffre-Barbe, M; Gardembas, M; Ingrand, P; Lacotte-Thierry, L; Legouffe, E; Olivier, G; Solal-Celigny, P, 2014) |
| "Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients." | 2.75 | Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. ( Bessho, M; Hagiwara, Y; Kohri, M; Niitsu, N; Okamoto, M; Takahashi, N; Tanae, K, 2010) |
| "To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL)." | 2.74 | [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. ( Cen, XN; Chen, H; Han, MZ; Han, XH; He, XH; Huang, H; Huang, HQ; Jiang, WQ; Liu, P; Ma, J; Ren, HY; Shen, XM; Shi, YK; Wang, C; Wang, JM; Yang, S; Zhou, SY; Zhu, J, 2009) |
| "CHOP-14 with the addition of rhG-CSF is safe and practicable in a large multicentre setting in patients aged 18-75 years." | 2.71 | Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). ( Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A, 2003) |
| "Tacrolimus was discontinued." | 2.48 | Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. ( Imai, H; Komatsu, N; Nakamura, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Wakabayashi, M, 2012) |
| "Although MALT lymphoma is the most common primary pulmonary lymphoma, it was present in only one of our patients, while seven patients had aggressive lymphoma." | 2.44 | Non-Hodgkin's lymphoma presenting as an endobronchial tumor: report of eight cases and literature review. ( Ben-Arieh, Y; Goralnik, L; Rowe, JM; Solomonov, A; Yigla, M; Zuckerman, T, 2008) |
| "Acute perforated appendicitis is a very rare initial presentation of appendiceal lymphoma." | 2.42 | Primary appendiceal lymphoma presenting as perforated acute appendicitis. ( Fu, TY; Tseng, HH; Wang, JS, 2004) |
| "Transformation of low-grade follicular lymphoma to high-grade diffuse large B cell lymphoma (DLBCL) is known." | 1.56 | Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse-a case report. ( Ashok, KP; Hassan, SA; Jacob, LA; Lokanatha, D; Lokesh, KN; Premalatha, CS; Rajeev, LK; Rudresha, AH; Smitha, S; Suma, MN; Suresh Babu, MC; Thottian, AGF, 2020) |
| "He was diagnosed with systemic lupus erythematosus at 34 years of age and was being treated with oral tacrolimus (3 mg/day) and predonine (10 mg/day) for the past 15 months." | 1.48 | A case of duodenal malignant lymphoma presenting as acute pancreatitis: systemic lupus erythematosus and immunosuppressive therapy as risk factors. ( Hamada, Y; Horiki, N; Inoue, H; Katsurahara, M; Miura, H; Nakamura, M; Okuse, H; Sakuno, T; Shiono, Y; Takei, Y; Takeuchi, T; Tanaka, K; Yamada, R, 2018) |
| "Histopathological subtypes consist of Burkitt's lymphoma (BL) in 32 (43." | 1.48 | Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan. ( Anwar, S; Faizan, M; Khan, S, 2018) |
| "Immune pancytopenia was diagnosed with bone marrow tests and the presence of autoantibodies; it promptly resolved after initiation of prednisolone therapy." | 1.43 | Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma. ( Nagai, Y; Nagashima, K; Sugita, Y; Tanaka, H, 2016) |
| " This report presents the case of a large PCL that was successfully treated by emergency surgical resection combined with postoperative chemotherapy." | 1.39 | Successful treatment of a large primary cardiac lymphoma by surgical resection combined with chemotherapy: report of a case. ( Fukushima, S; Kawamura, T; Miyagawa, S; Nishi, H; Saito, S; Sakaguchi, T; Sawa, Y; Yamauchi, T; Yoshikawa, Y, 2013) |
| "Thrombocytopenia was shown to be an independently poor prognostic factor in the multivariate analysis of overall survival (hazard ratio [HR], 3." | 1.38 | Prognostic value of platelet count in diffuse large B-cell lymphoma. ( Chen, LP; Lin, SJ; Yu, MS, 2012) |
| "However, the occurrence of ML in systemic sclerosis (SSc) patients has rarely been reported." | 1.35 | [Mediastinal large B-cell lymphoma associated with systemic sclerosis]. ( Arai, H; Arai, Y; Iso, H; Mitani, K; Nakamura, Y; Tadokoro, J; Yamagata, T, 2009) |
| " However, it is unknown if higher RDI in chemotherapy when combined with rituximab leads to a better outcome in aggressive B-cell lymphoma." | 1.35 | Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. ( Aimoto, M; Aimoto, R; Hino, M; Inoue, E; Kanashima, H; Koh, H; Koh, KR; Mugitani, A; Nakamae, H; Nakane, T; Nakao, Y; Ohsawa, M; Ohta, K; Sakamoto, E; Takeoka, Y; Terada, Y; Teshima, H; Yamane, T, 2009) |
| "Ninety-six patients with gastric MALT lymphoma, including 17 patients with areas of diffuse large B-cell lymphoma, were treated by H." | 1.33 | Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. ( Esaki, M; Iida, M; Matsumoto, H; Matsumoto, T; Nakamura, S; Suekane, H; Yao, T, 2005) |
| "We examined the efficacy and adverse effects of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) or THP-COP (pirarubicin, cyclophosphamide, vincristin, prednisone) in previously untreated old-old and extremely old patients with diffuse large B cell lymphoma (DLBCL)." | 1.33 | [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma]. ( Abe, S; Fujii, H; Iwamoto, T; Kanaya, K; Kikukawa, M; Kiuchi, A; Miyazaki, K; Shin, K, 2006) |
| "Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course." | 1.32 | A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. ( Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD, 2003) |
| "Diagnosed as having a testicular tumor by ultrasonography and MRI, he underwent orchiectomy." | 1.32 | [Testicular malignant lymphoma: a case report]. ( Iwasawa, T; Kuroda, K; Masuda, E; Matsushima, M; Satou, D; Sawada, Y; Tajima, M; Takeuchi, Y; Yabuki, D, 2003) |
| "The diagnosis of Wegener's Granulomatosis (WG) was formed on the base of clinical features and result of pathologic examination of surgical specimen from the paranasal sinuses." | 1.31 | [Diffuse large B-cell lymphoma mimicking Wegener's granulomatosis]. ( Dobkowski, P; Gawryluk, D; Słodkowska, J; Wiatr, E, 2002) |
| "In this case, congestive heart failure developed even though the total dose of pirarubicin was lower than in previous reports of this complication." | 1.31 | [CHF arising after low dose THP-COP chemotherapy in an elderly patient with malignant lymphoma]. ( Doi, N; Fujimoto, S; Hashimoto, T; Matoba-Ueno, K; Nakamura, S; Nishino, T; Shiiki, H; Yamano, S, 2001) |
| "We treated three cases of interstitial pneumonitis (IP) in 26 elderly (> or = 65 years old) patients with non-Hodgkin's lymphoma (NHL) who received the same chemotherapeutic protocol including granulocyte colony-stimulating factor (G-CSF) administration." | 1.30 | Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma. ( Abe, T; Hasegawa, Y; Kamoshita, M; Kobayashi, T; Kojima, H; Nagasawa, T; Ninomiya, H; Ohtani, K, 1997) |
| "Multiple brain tumors were found and diagnosed as having B-cell, diffuse large cell type malignant lymphoma." | 1.30 | [A case of malignant lymphoma after renal transplantation]. ( Ikeda, K; Inoue, S; Matsuura, O; Murakami, S; Oyama, H; Sugiyama, T; Yamao, K, 1997) |
| "Pneumonitis is a well recognized side effect of this drug, but occurs at low doses in the treatment of NHL." | 1.30 | Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodgkin's lymphoma. ( Bloor, AJ; Marcus, RE; Seale, JR, 1998) |
| "The initial clinical diagnosis was left testicular tumor." | 1.28 | Malignant lymphoma of the testis presenting as primary testicular tumor. ( Kanetake, H; Minami, Y; Nomata, K; Saha, PK; Saito, Y; Sakai, H, 1991) |
| "15 patients with malignant lymphomas (stage III B or IV) who had become resistant to previous combination chemotherapy were treated with DTIC." | 1.26 | Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations. ( Donner, L; Klener, P, 1977) |
| "For patients with lymphosarcoma the average duration of complete remission was 26." | 1.26 | [Polychemotherapy in non-hodgkin lymphoma with a modified MOPP scheme (author's transl)]. ( Hiller, E; Schmülling, RM; Tigges, FJ; Waller, HD; Wilms, K, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (7.71) | 18.7374 |
| 1990's | 45 (12.40) | 18.2507 |
| 2000's | 112 (30.85) | 29.6817 |
| 2010's | 154 (42.42) | 24.3611 |
| 2020's | 24 (6.61) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, S | 1 |
| Sun, L | 1 |
| Takahashi, H | 2 |
| Sano, T | 1 |
| Kawamura, S | 2 |
| Sano, K | 1 |
| Miyasaka, R | 1 |
| Yamazaki, T | 1 |
| Sakakibara, M | 1 |
| Abe, T | 2 |
| Hashimoto, K | 1 |
| Nagaoka, M | 1 |
| Kamata, M | 1 |
| Naito, S | 2 |
| Aoyama, T | 1 |
| Moriya, R | 1 |
| Takeuchi, Y | 2 |
| Jeong, SH | 1 |
| Kim, SJ | 3 |
| Yoon, DH | 1 |
| Park, Y | 2 |
| Kang, HJ | 3 |
| Koh, Y | 1 |
| Lee, GW | 2 |
| Lee, WS | 3 |
| Yang, DH | 4 |
| Do, YR | 2 |
| Kim, MK | 3 |
| Yoo, KH | 1 |
| Choi, YS | 1 |
| Yun, HJ | 1 |
| Yi, JH | 1 |
| Jo, JC | 2 |
| Eom, HS | 3 |
| Kwak, JY | 3 |
| Shin, HJ | 4 |
| Park, BB | 1 |
| Hyun, SY | 1 |
| Yi, SY | 1 |
| Kwon, JH | 1 |
| Oh, SY | 7 |
| Kim, HJ | 5 |
| Sohn, BS | 1 |
| Won, JH | 1 |
| Kim, SH | 2 |
| Lee, HS | 3 |
| Suh, C | 3 |
| Kim, WS | 4 |
| Lombion, N | 1 |
| Robin, P | 1 |
| Tempescul, A | 1 |
| LE Roux, PY | 1 |
| Schick, U | 1 |
| Guillerm, G | 1 |
| Ianotto, JC | 1 |
| Berthou, C | 1 |
| Salaün, PY | 1 |
| Abgral, R | 1 |
| Jobanputra, K | 1 |
| Nayak, L | 2 |
| Jain, H | 2 |
| Shet, T | 2 |
| Epari, S | 1 |
| Bonda, VNA | 1 |
| Thorat, J | 2 |
| Bagal, B | 2 |
| Laskar, S | 1 |
| Rangarajan, V | 2 |
| Agrawal, A | 1 |
| Gujral, S | 2 |
| Khanna, N | 1 |
| Goda, JS | 1 |
| Sengar, M | 2 |
| Choi, JH | 2 |
| Lim, I | 1 |
| Byun, BH | 1 |
| Kim, BI | 1 |
| Choi, CW | 3 |
| Shin, DY | 1 |
| Lim, SM | 1 |
| Sridhar, E | 1 |
| Gota, V | 1 |
| Laskar, SS | 1 |
| Alahari, A | 1 |
| Agarwal, A | 1 |
| Sharma, N | 1 |
| Gupta, H | 1 |
| Kannan, S | 1 |
| Kumar, S | 1 |
| Menon, H | 1 |
| Kawamura, T | 2 |
| Moriguchi, M | 1 |
| Konari, S | 1 |
| Murai, K | 1 |
| Kato, Y | 1 |
| Obara, W | 1 |
| Miyazaki, Y | 2 |
| Tokuyama, S | 1 |
| Fukuda, Y | 1 |
| Michiura, T | 1 |
| Hayashi, N | 1 |
| Morimoto, M | 1 |
| Yokoya, Y | 1 |
| Yamabe, K | 1 |
| Kim, YR | 1 |
| Kim, JS | 3 |
| Bae, SH | 1 |
| Lee, JH | 3 |
| Oh, SJ | 1 |
| Yoon, SS | 1 |
| Nam, SH | 1 |
| Shim, H | 1 |
| Park, JS | 1 |
| Mun, YC | 1 |
| Matsumoto, M | 1 |
| Takakura, H | 1 |
| Usui, Y | 1 |
| Sugimoto, T | 2 |
| Yabe, M | 1 |
| Misaki, K | 1 |
| Kawaguchi, K | 1 |
| Mellert, K | 1 |
| Martin, M | 1 |
| Lennerz, JK | 1 |
| Lüdeke, M | 1 |
| Staiger, AM | 1 |
| Kreuz, M | 1 |
| Löffler, M | 1 |
| Schmitz, N | 3 |
| Trümper, L | 2 |
| Feller, AC | 1 |
| Hartmann, S | 1 |
| Hansmann, ML | 1 |
| Klapper, W | 1 |
| Stein, H | 1 |
| Rosenwald, A | 4 |
| Ott, G | 2 |
| Ziepert, M | 3 |
| Möller, P | 1 |
| Fukuta, T | 1 |
| Nishimura, N | 1 |
| Shirouchi, Y | 1 |
| Inoue, N | 1 |
| Uryu, H | 1 |
| Kusano, Y | 1 |
| Mishima, Y | 1 |
| Yokoyama, M | 2 |
| Tsuyama, N | 1 |
| Takeuchi, K | 3 |
| Terui, Y | 1 |
| Xia, Y | 1 |
| Zhang, X | 1 |
| Wang, B | 2 |
| Yu, Y | 1 |
| Zhang, Y | 1 |
| Hao, X | 1 |
| Zhao, H | 1 |
| Yang, S | 3 |
| Sun, Q | 1 |
| Wang, Y | 1 |
| Nijland, M | 1 |
| Bakker, M | 1 |
| Meijer, K | 1 |
| Plattel, W | 1 |
| Guler, Y | 1 |
| Ucpinar, B | 1 |
| Erbin, A | 1 |
| Suresh Babu, MC | 1 |
| Thottian, AGF | 1 |
| Lokanatha, D | 1 |
| Jacob, LA | 1 |
| Lokesh, KN | 1 |
| Rudresha, AH | 1 |
| Rajeev, LK | 1 |
| Smitha, S | 1 |
| Hassan, SA | 1 |
| Ashok, KP | 1 |
| Premalatha, CS | 1 |
| Suma, MN | 1 |
| Nakamura, M | 2 |
| Saeki, K | 1 |
| Egashira, R | 1 |
| Egashira, Y | 1 |
| Kojima, K | 2 |
| Katsuya, H | 1 |
| Kizuka-Sano, H | 1 |
| Yokoo, M | 1 |
| Kidoguchi, K | 1 |
| Yamaguchi, K | 1 |
| Nishioka, A | 1 |
| Ureshino, H | 2 |
| Kubota, Y | 3 |
| Ando, T | 2 |
| Ohshima, K | 7 |
| Kimura, S | 2 |
| Maggen, C | 1 |
| Dierickx, D | 1 |
| Cardonick, E | 1 |
| Mhallem Gziri, M | 1 |
| Cabrera-Garcia, A | 1 |
| Shmakov, RG | 1 |
| Avivi, I | 1 |
| Masturzo, B | 1 |
| Duvekot, JJ | 1 |
| Ottevanger, PB | 1 |
| O'Laughlin, A | 1 |
| Polushkina, E | 1 |
| Van Calsteren, K | 1 |
| Woei-A-Jin, FJSH | 1 |
| Amant, F | 1 |
| Jiang, C | 1 |
| Ding, C | 1 |
| Xu, J | 1 |
| Teng, Y | 1 |
| Chen, J | 1 |
| Wang, Z | 1 |
| Zhou, Z | 2 |
| Wang, XD | 1 |
| Guo, B | 1 |
| Zhai, B | 1 |
| Yang, B | 1 |
| Fan, H | 1 |
| Lu, XC | 1 |
| Li, SX | 1 |
| Zhu, HL | 1 |
| Lisenko, K | 1 |
| Dingeldein, G | 1 |
| Cremer, M | 1 |
| Kriegsmann, M | 1 |
| Ho, AD | 2 |
| Rieger, M | 1 |
| Witzens-Harig, M | 1 |
| Prasad, SN | 1 |
| Lal, H | 1 |
| Jaiswal, S | 1 |
| Das, KK | 1 |
| Bernardes, C | 1 |
| Russo, P | 1 |
| Carvalho, D | 1 |
| Saiote, J | 1 |
| Ramos, J | 1 |
| Faizan, M | 1 |
| Anwar, S | 1 |
| Khan, S | 1 |
| Yamada, R | 1 |
| Sakuno, T | 1 |
| Inoue, H | 3 |
| Miura, H | 1 |
| Takeuchi, T | 3 |
| Shiono, Y | 1 |
| Okuse, H | 1 |
| Katsurahara, M | 1 |
| Hamada, Y | 1 |
| Tanaka, K | 1 |
| Horiki, N | 1 |
| Takei, Y | 1 |
| Hara, T | 9 |
| Yoshikawa, T | 4 |
| Goto, H | 3 |
| Sawada, M | 5 |
| Yamada, T | 6 |
| Fukuno, K | 3 |
| Kasahara, S | 6 |
| Shibata, Y | 2 |
| Matsumoto, T | 4 |
| Mabuchi, R | 1 |
| Nakamura, N | 6 |
| Nakamura, H | 4 |
| Ninomiya, S | 3 |
| Kitagawa, J | 5 |
| Kanemura, N | 7 |
| Nannya, Y | 1 |
| Katsumura, N | 2 |
| Takahashi, T | 7 |
| Kito, Y | 2 |
| Takami, T | 7 |
| Miyazaki, T | 3 |
| Shimizu, M | 4 |
| Tsurumi, H | 8 |
| Sakurai, M | 1 |
| Karigane, D | 1 |
| Kasahara, H | 2 |
| Tanigawa, T | 1 |
| Ishida, A | 1 |
| Murakami, H | 1 |
| Kikuchi, M | 3 |
| Kohashi, S | 2 |
| Shikuma, A | 1 |
| Sawada, T | 3 |
| Uchiyama, H | 1 |
| Shiraishi, J | 1 |
| Oshiro, M | 1 |
| Kawaji, Y | 1 |
| Koshi, N | 1 |
| Friedrichs, B | 1 |
| Nickelsen, M | 1 |
| Altmann, B | 1 |
| Haenel, M | 1 |
| Viardot, A | 1 |
| Schmidt, C | 1 |
| Ruebe, C | 1 |
| Loeffler, M | 3 |
| Pfreundschuh, M | 4 |
| Glass, B | 2 |
| Lenz, G | 1 |
| Kari, E | 1 |
| Teppo, HR | 1 |
| Haapasaari, KM | 2 |
| Kuusisto, MEL | 1 |
| Lemma, A | 1 |
| Karihtala, P | 1 |
| Pirinen, R | 1 |
| Soini, Y | 1 |
| Jantunen, E | 1 |
| Turpeenniemi-Hujanen, T | 2 |
| Kuittinen, O | 2 |
| Park, LC | 2 |
| Song, YJ | 1 |
| Kim, DJ | 1 |
| Kim, MJ | 1 |
| Jeong, JY | 1 |
| Bostan, E | 1 |
| Akdogan, N | 1 |
| Saglam Ayhan, A | 1 |
| Ersoy Evans, S | 1 |
| Yamashita, A | 1 |
| Tokuda, M | 1 |
| Matsuo, M | 1 |
| Irie, J | 1 |
| Tateishi, Y | 1 |
| Mutsukura, K | 1 |
| Djebbari, F | 1 |
| Browning, JA | 1 |
| Stanton, L | 1 |
| Booth, S | 1 |
| Hildyard, C | 1 |
| Willan, J | 1 |
| Bosworth, J | 1 |
| Vora, SM | 1 |
| Hatton, CSR | 1 |
| Collins, GP | 2 |
| Eyre, TA | 1 |
| Mase, H | 1 |
| Ogawa, Y | 1 |
| Takeuchi, J | 1 |
| Genda, Y | 1 |
| Ichiba, S | 1 |
| Sakamoto, A | 1 |
| Gao, Y | 2 |
| Xie, Y | 1 |
| Liu, L | 1 |
| Xue, H | 1 |
| Hou, M | 1 |
| Zhang, M | 1 |
| Guo, P | 1 |
| Yao, H | 1 |
| Shao, Z | 1 |
| Xie, X | 1 |
| Zhu, J | 3 |
| Aoki, K | 2 |
| Tabata, S | 2 |
| Kurata, M | 1 |
| Matsushita, A | 2 |
| Nagai, K | 2 |
| Ishikawa, T | 1 |
| Hiramoto, N | 1 |
| Kobayashi, Y | 4 |
| Nomoto, J | 1 |
| Maruyama, D | 1 |
| Watanabe, T | 3 |
| Tochigi, N | 1 |
| Furuta, K | 1 |
| Takeda, K | 1 |
| Chuman, H | 1 |
| Yagyu, S | 1 |
| Hosoi, H | 1 |
| Tobinai, K | 2 |
| Zentar, A | 1 |
| Tarchouli, M | 1 |
| Elkaoui, H | 1 |
| Belhamidi, MS | 1 |
| Ratbi, MB | 1 |
| Bouchentouf, SM | 1 |
| Ali, AA | 1 |
| Bounaim, A | 1 |
| Sair, K | 1 |
| Alcoceba, M | 1 |
| Sebastián, E | 1 |
| Marín, L | 1 |
| Balanzategui, A | 1 |
| Sarasquete, ME | 1 |
| Chillón, MC | 1 |
| Jiménez, C | 1 |
| Puig, N | 1 |
| Corral, R | 1 |
| Pardal, E | 1 |
| Grande, C | 1 |
| Bello, JL | 1 |
| Albo, C | 1 |
| de la Cruz, F | 1 |
| Panizo, C | 1 |
| Martín, A | 1 |
| González-Barca, E | 1 |
| Caballero, MD | 1 |
| San Miguel, JF | 1 |
| García-Sanz, R | 1 |
| González, M | 1 |
| Lowry, L | 1 |
| Smith, P | 4 |
| Cunningham, D | 2 |
| Linch, DC | 5 |
| Fields, PA | 1 |
| Townsend, W | 1 |
| Webb, A | 1 |
| Counsell, N | 1 |
| Pocock, C | 1 |
| Jack, A | 2 |
| El-Mehidi, N | 1 |
| Johnson, PW | 1 |
| Radford, J | 1 |
| Cunnningham, D | 1 |
| Senapati, J | 1 |
| Devasia, AJ | 1 |
| Sudhakar, S | 1 |
| Viswabandya, A | 1 |
| Tanaka, H | 4 |
| Yoshino, K | 1 |
| Sakaida, E | 1 |
| Hashimoto, S | 1 |
| Takeda, Y | 1 |
| Kawajiri, C | 1 |
| Takagi, T | 1 |
| Nakaseko, C | 1 |
| Long, X | 1 |
| Yu, N | 1 |
| Zeng, A | 1 |
| Long, F | 1 |
| Wang, XJ | 1 |
| Ishii, Y | 1 |
| Tomita, N | 4 |
| Tateishi, U | 1 |
| Ishiyama, Y | 1 |
| Yamamoto, E | 2 |
| Hattori, Y | 1 |
| Hagihara, M | 1 |
| Yamazaki, E | 2 |
| Ishigatsubo, Y | 5 |
| Cai, QC | 1 |
| Wang, XX | 1 |
| Cai, QQ | 1 |
| Lin, ZX | 1 |
| Bai, B | 1 |
| Guo, Y | 2 |
| Huang, HQ | 2 |
| Kreher, S | 1 |
| Lammer, F | 1 |
| Augustin, D | 1 |
| Pezzutto, A | 1 |
| Baldus, CD | 1 |
| Alvarez, R | 1 |
| Esteves, S | 1 |
| Chacim, S | 1 |
| Carda, J | 1 |
| Mota, A | 1 |
| Guerreiro, M | 1 |
| Barbosa, I | 1 |
| Moita, F | 1 |
| Teixeira, A | 1 |
| Coutinho, J | 1 |
| Príncipe, F | 1 |
| Mariz, JM | 1 |
| Silva, MG | 1 |
| Abe, H | 1 |
| Kamimura, K | 1 |
| Mamizu, M | 1 |
| Shibazaki, Y | 1 |
| Ishiguro, T | 1 |
| Katada, S | 1 |
| Nishiyama, YK | 1 |
| Takahashi, Y | 2 |
| Hatano, YY | 1 |
| Mizuno, K | 1 |
| Watanabe, Y | 2 |
| Nagashima, A | 1 |
| Takizawa, J | 2 |
| Takeuchi, M | 2 |
| Kawai, H | 1 |
| Nomoto, M | 1 |
| Sone, H | 2 |
| Nishizawa, M | 1 |
| Aoyagi, Y | 1 |
| Lee, HY | 1 |
| Lee, KH | 1 |
| Hyun, MS | 2 |
| Koh, SA | 1 |
| Cho, HS | 1 |
| Miyazaki, K | 3 |
| Yamaguchi, M | 1 |
| Cheng, C | 1 |
| Gallagher, EM | 1 |
| Yeh, JY | 1 |
| Earl, MA | 1 |
| Yoshimura, T | 1 |
| Nakane, T | 3 |
| Kamesaki, T | 1 |
| Inaba, A | 1 |
| Nishimoto, M | 1 |
| Mukai, S | 1 |
| Sakabe, M | 1 |
| Ohsawa, M | 2 |
| Fujino, K | 1 |
| Koh, H | 2 |
| Nakao, Y | 2 |
| Nakamae, H | 3 |
| Hino, M | 3 |
| Olivier, G | 1 |
| Clavert, A | 1 |
| Lacotte-Thierry, L | 1 |
| Gardembas, M | 1 |
| Escoffre-Barbe, M | 1 |
| Brion, A | 1 |
| Cumin, I | 1 |
| Legouffe, E | 1 |
| Solal-Celigny, P | 1 |
| Chabin, M | 1 |
| Ingrand, P | 1 |
| Colombat, P | 1 |
| Delwail, V | 1 |
| Yamamoto, K | 3 |
| Straus, DJ | 1 |
| Hamlin, PA | 1 |
| Matasar, MJ | 1 |
| Lia Palomba, M | 1 |
| Drullinsky, PR | 1 |
| Zelenetz, AD | 1 |
| Gerecitano, JF | 1 |
| Noy, A | 1 |
| Hamilton, AM | 1 |
| Elstrom, R | 1 |
| Wegner, B | 1 |
| Wortman, K | 1 |
| Cella, D | 1 |
| Molina, TJ | 2 |
| Canioni, D | 2 |
| Copie-Bergman, C | 1 |
| Recher, C | 2 |
| Brière, J | 2 |
| Haioun, C | 5 |
| Berger, F | 2 |
| Fermé, C | 2 |
| Copin, MC | 1 |
| Casasnovas, O | 2 |
| Thieblemont, C | 2 |
| Petrella, T | 1 |
| Leroy, K | 2 |
| Salles, G | 2 |
| Fabiani, B | 1 |
| Morschauser, F | 1 |
| Mounier, N | 2 |
| Coiffier, B | 5 |
| Jardin, F | 2 |
| Gaulard, P | 3 |
| Jais, JP | 2 |
| Tilly, H | 4 |
| Bhagat, P | 1 |
| Sachdeva, MU | 1 |
| Sharma, P | 1 |
| Naseem, S | 1 |
| Ahluwalia, J | 1 |
| Das, R | 1 |
| Varma, N | 1 |
| Law, A | 1 |
| Malhotra, P | 1 |
| Houssaini, GS | 1 |
| Tahiri, L | 1 |
| Ibrahimi, A | 1 |
| Tizniti, S | 1 |
| Elmrini, A | 1 |
| Harzy, T | 1 |
| Nakajima, Y | 1 |
| Itabashi, M | 1 |
| Miyashita, K | 1 |
| Watanabe, R | 2 |
| Tachibana, T | 1 |
| Takasaki, H | 1 |
| Kawasaki, R | 1 |
| Tanaka, M | 3 |
| Hashimoto, C | 2 |
| Taguchi, J | 1 |
| Fujimaki, K | 1 |
| Sakai, R | 2 |
| Fujita, H | 1 |
| Fujisawa, S | 1 |
| Harano, H | 1 |
| Motomura, S | 1 |
| Fayad, L | 1 |
| Ansell, SM | 1 |
| Advani, R | 2 |
| Stuart, R | 1 |
| Bartlett, NL | 1 |
| Forero-Torres, A | 1 |
| Kuliczkowski, K | 1 |
| Belada, D | 1 |
| Ng, E | 1 |
| Drachman, JG | 1 |
| Brauner, S | 1 |
| Zhou, W | 1 |
| Backlin, C | 1 |
| Green, TM | 1 |
| Folkersen, L | 1 |
| Ivanchenko, M | 1 |
| Löfström, B | 1 |
| Xu-Monette, ZY | 1 |
| Young, KH | 2 |
| Møller Pedersen, L | 2 |
| Boe Møller, M | 1 |
| Sundström, C | 1 |
| Enblad, G | 1 |
| Baecklund, E | 1 |
| Wahren-Herlenius, M | 1 |
| Pedersen, MØ | 1 |
| Poulsen, TS | 1 |
| Gang, AO | 1 |
| Knudsen, H | 1 |
| Lauritzen, AF | 1 |
| Pedersen, M | 1 |
| Nielsen, SL | 1 |
| Brown, P | 1 |
| Høgdall, E | 1 |
| Nørgaard, P | 1 |
| Peng, JX | 1 |
| Wang, LZ | 1 |
| Tan, ZJ | 1 |
| Zhong, XS | 1 |
| Huang, YX | 1 |
| Diao, JF | 1 |
| He, JM | 1 |
| Tsuda, M | 1 |
| Nakashima, Y | 1 |
| Ikeda, M | 1 |
| Shimada, S | 1 |
| Nomura, M | 1 |
| Matsushima, T | 1 |
| Takahashi, S | 2 |
| Aishima, S | 1 |
| Oda, Y | 1 |
| Shiratsuchi, M | 1 |
| Takayanagi, R | 1 |
| Tashiro, R | 1 |
| Kanamori, M | 2 |
| Suzuki, H | 2 |
| Utsunomiya, A | 1 |
| Meguro, K | 1 |
| Uenohara, H | 2 |
| Tominaga, T | 2 |
| Gang, GW | 1 |
| Lee, SR | 1 |
| Sung, HJ | 1 |
| Kim, DS | 1 |
| Kim, BS | 3 |
| Kate, AH | 1 |
| Sandeepa, HS | 1 |
| Khare, S | 1 |
| Lokeshwar, N | 1 |
| Shetty, S | 1 |
| Tulasigeri, C | 1 |
| Chhajed, PN | 1 |
| Wästerlid, T | 1 |
| Hartman, L | 1 |
| Székely, E | 1 |
| Jerkeman, M | 3 |
| Goto, N | 7 |
| Shiraki, M | 1 |
| Bains, S | 1 |
| Vidhya, N | 1 |
| Kim, U | 1 |
| Shanti, R | 1 |
| Devanand, J | 1 |
| Iioka, F | 1 |
| Izumi, K | 1 |
| Kamoda, Y | 1 |
| Akasaka, T | 1 |
| Ohno, H | 1 |
| Nitta, D | 1 |
| Kinugawa, K | 1 |
| Imamura, T | 1 |
| Hatano, M | 1 |
| Ono, M | 2 |
| Nakamura, F | 1 |
| Kurokawa, M | 2 |
| Komuro, I | 1 |
| Friedberg, JW | 2 |
| Shimoyama, Y | 1 |
| Sugimoto, K | 2 |
| Kotake, M | 1 |
| Uehara, D | 1 |
| Kamide, Y | 1 |
| Kuribayashi, S | 1 |
| Kawamura, O | 1 |
| Kusano, M | 1 |
| Handa, H | 1 |
| Hirato, J | 1 |
| Yamada, M | 1 |
| Itamura, H | 1 |
| Jinnai, S | 1 |
| Doi, K | 1 |
| Kurogi, K | 1 |
| Miyahara, M | 1 |
| Nam, SJ | 1 |
| Kim, S | 2 |
| Paik, JH | 1 |
| Kim, TM | 1 |
| Heo, DS | 1 |
| Kim, CW | 1 |
| Jeon, YK | 1 |
| Akamatsu, Y | 1 |
| Fridrik, MA | 2 |
| Jaeger, U | 2 |
| Petzer, A | 1 |
| Willenbacher, W | 1 |
| Keil, F | 1 |
| Lang, A | 1 |
| Andel, J | 1 |
| Burgstaller, S | 1 |
| Krieger, O | 2 |
| Oberaigner, W | 1 |
| Sihorsch, K | 1 |
| Greil, R | 2 |
| Kawamoto, K | 1 |
| Miyoshi, H | 1 |
| Yoshida, N | 1 |
| Hedermann, G | 1 |
| Marquart, HV | 1 |
| Vissing, J | 1 |
| Ji, D | 1 |
| Li, Q | 1 |
| Cao, J | 1 |
| Lv, F | 1 |
| Liu, X | 1 |
| Wang, L | 1 |
| Luo, Z | 1 |
| Chang, J | 2 |
| Wu, X | 1 |
| Hong, X | 1 |
| Lv, X | 1 |
| Feng, L | 1 |
| Ge, X | 1 |
| Lu, K | 1 |
| Wang, X | 1 |
| Kanemasa, Y | 1 |
| Shimoyama, T | 1 |
| Sasaki, Y | 1 |
| Tamura, M | 1 |
| Omuro, Y | 1 |
| Hishima, T | 1 |
| Maeda, Y | 1 |
| Stephens, DM | 1 |
| Li, H | 1 |
| LeBlanc, ML | 1 |
| Puvvada, SD | 1 |
| Persky, D | 1 |
| Smith, SM | 1 |
| Khan, MA | 1 |
| Garg, K | 1 |
| Bhurani, D | 1 |
| Agarwal, NB | 1 |
| Nagashima, K | 1 |
| Nagai, Y | 2 |
| Sugita, Y | 1 |
| Pauly, F | 1 |
| Fjordén, K | 1 |
| Leppä, S | 2 |
| Holte, H | 2 |
| Björkholm, M | 1 |
| Fluge, Ø | 1 |
| Eriksson, M | 1 |
| Isinger-Ekstrand, A | 1 |
| Borrebaeck, CA | 1 |
| Wingren, C | 1 |
| Møller, MB | 1 |
| Colleoni, GW | 1 |
| Sánchez-Beato, M | 1 |
| Kerbauy, FR | 1 |
| Eickhoff, JC | 1 |
| Young, AH | 1 |
| Piris, MA | 1 |
| Oberley, TD | 1 |
| Rehrauer, WM | 1 |
| Kahl, BS | 1 |
| Malter, JS | 1 |
| Campo, E | 2 |
| Delabie, J | 2 |
| Gascoyne, RD | 3 |
| Rimsza, L | 2 |
| Huang, J | 1 |
| Braziel, RM | 2 |
| Jaffe, ES | 1 |
| Wilson, WH | 1 |
| Staudt, LM | 2 |
| Vose, JM | 5 |
| Chan, WC | 4 |
| Weisenburger, DD | 5 |
| Greiner, TC | 4 |
| Fu, K | 1 |
| Choi, WW | 1 |
| Perry, KD | 1 |
| Smith, LM | 2 |
| Shi, X | 1 |
| Hans, CP | 2 |
| Bierman, PJ | 3 |
| Bociek, RG | 3 |
| Armitage, JO | 6 |
| Ladha, A | 1 |
| Haider, G | 1 |
| Su, CF | 1 |
| Tsai, HJ | 1 |
| Kuo, C | 1 |
| Chen, GD | 1 |
| Lin, LY | 1 |
| Huang, CC | 1 |
| Luo, KH | 1 |
| Kim, HY | 1 |
| Lee, S | 1 |
| Lee, DM | 1 |
| Kwon, HC | 1 |
| Hong, SH | 1 |
| Yoon, JH | 1 |
| Gotoh, M | 1 |
| Kitahara, T | 1 |
| Iguchi, T | 1 |
| Izumi, M | 1 |
| Mukai, K | 3 |
| Ohyashiki, K | 3 |
| Yeo, W | 1 |
| Chan, TC | 1 |
| Leung, NW | 1 |
| Lam, WY | 1 |
| Mo, FK | 1 |
| Chu, MT | 1 |
| Chan, HL | 1 |
| Hui, EP | 1 |
| Lei, KI | 1 |
| Mok, TS | 1 |
| Chan, PK | 1 |
| Precupanu, CM | 1 |
| Girodet, J | 1 |
| Mariani, P | 1 |
| Zanni, M | 1 |
| Mathiot, C | 1 |
| Escande, MC | 1 |
| Brault, P | 1 |
| Decaudin, D | 1 |
| Asagi, A | 1 |
| Miyake, Y | 1 |
| Ando, M | 1 |
| Yasuhara, H | 1 |
| Matsumoto, K | 1 |
| Takahara, M | 1 |
| Kawai, D | 1 |
| Kaji, E | 1 |
| Toyokawa, T | 1 |
| Onishi, T | 1 |
| Miyatani, K | 1 |
| Nakatsu, M | 1 |
| Arai, H | 1 |
| Iso, H | 1 |
| Arai, Y | 1 |
| Tadokoro, J | 1 |
| Nakamura, Y | 3 |
| Yamagata, T | 1 |
| Mitani, K | 1 |
| Suzuki, Y | 1 |
| Niitsu, N | 4 |
| Hayama, M | 2 |
| Katayama, T | 1 |
| Ishii, R | 1 |
| Osaka, M | 1 |
| Danbara, M | 1 |
| Horie, R | 1 |
| Yoshida, T | 2 |
| Higashihara, M | 2 |
| Held, G | 1 |
| Murakami, Y | 1 |
| Yamanouchi, J | 1 |
| Azuma, T | 1 |
| Ikeda, Y | 1 |
| Narumi, H | 1 |
| Fujiwara, H | 1 |
| Yakushijin, Y | 2 |
| Hato, T | 1 |
| Yasukawa, M | 3 |
| Faris, JE | 1 |
| LaCasce, AS | 1 |
| Nyman, H | 1 |
| Karjalainen-Lindsberg, ML | 1 |
| Banham, AH | 1 |
| Niscola, P | 1 |
| Palombi, M | 1 |
| Trawinska, MM | 1 |
| Scaramucci, L | 1 |
| Giovannini, M | 1 |
| Perrotti, AP | 1 |
| Fabritiis, Pd | 1 |
| Fratoni, S | 1 |
| Sonet, A | 1 |
| Bosly, A | 3 |
| Maxwell, SA | 1 |
| Li, Z | 1 |
| Jaya, D | 1 |
| Ballard, S | 1 |
| Ferrell, J | 1 |
| Fu, H | 1 |
| Yago, K | 1 |
| Yanagita, S | 1 |
| Aono, M | 1 |
| Matsuo, K | 1 |
| Shimada, H | 1 |
| Hosoi, M | 1 |
| Yamamoto, G | 1 |
| Imai, Y | 2 |
| Feldmann, R | 1 |
| Schierl, M | 1 |
| Sittenthaler, M | 1 |
| Jahn, R | 1 |
| Wogritsch, C | 1 |
| Cerroni, L | 1 |
| Steiner, A | 1 |
| Breier, F | 1 |
| Yasuda, I | 2 |
| Moriwaki, H | 6 |
| Horváth, B | 1 |
| Demeter, J | 1 |
| Eros, N | 1 |
| Hársing, J | 1 |
| Csomor, J | 1 |
| Matolcsy, A | 1 |
| Bottlik, G | 1 |
| Gyori, G | 1 |
| Marschalkó, M | 1 |
| Kárpáti, S | 1 |
| Nakazato, T | 2 |
| Suzuki, K | 2 |
| Mihara, A | 1 |
| Sanada, Y | 1 |
| Kakimoto, T | 2 |
| Yoshida, S | 2 |
| Sieniawski, M | 1 |
| Bhartia, S | 1 |
| Wilkinson, J | 1 |
| Proctor, SJ | 1 |
| Terada, Y | 2 |
| Aimoto, R | 1 |
| Kanashima, H | 1 |
| Sakamoto, E | 1 |
| Aimoto, M | 1 |
| Inoue, E | 1 |
| Takeoka, Y | 1 |
| Koh, KR | 1 |
| Yamane, T | 2 |
| Ohta, K | 3 |
| Mugitani, A | 1 |
| Teshima, H | 1 |
| Chaiwatanatorn, K | 1 |
| Stamaratis, G | 1 |
| Opeskin, K | 1 |
| Firkin, F | 1 |
| Nandurkar, H | 1 |
| Kyllönen, H | 1 |
| Pasanen, AK | 1 |
| Westin, J | 1 |
| McLaughlin, P | 1 |
| Kinoshita, T | 3 |
| Park, SM | 1 |
| Shim, CY | 1 |
| Choi, D | 1 |
| Kim, SA | 1 |
| Choi, EY | 1 |
| Ha, JW | 1 |
| Chung, N | 1 |
| Kim, IS | 1 |
| Kim, DC | 1 |
| Kim, HG | 1 |
| Kong, SY | 1 |
| Hwang, SH | 1 |
| Lee, EY | 1 |
| Hoshi, M | 1 |
| Ito, H | 1 |
| Takemura, M | 1 |
| Saito, K | 3 |
| Seishima, M | 2 |
| Chin, K | 1 |
| Fujimura, M | 1 |
| Sekit, N | 1 |
| Mikami, K | 1 |
| Kamijima, S | 1 |
| Ichikawa, T | 2 |
| MORI, M | 1 |
| INOUE, D | 1 |
| KIMURA, T | 1 |
| SHIMOJI, S | 1 |
| TOGAMI, K | 1 |
| Takafuta, T | 1 |
| Shi, YK | 3 |
| Han, XH | 1 |
| Ma, J | 1 |
| Ren, HY | 1 |
| Cen, XN | 1 |
| Zhou, SY | 2 |
| Wang, C | 1 |
| Jiang, WQ | 1 |
| Wang, JM | 1 |
| Chen, H | 1 |
| Han, MZ | 1 |
| Huang, H | 1 |
| Shen, XM | 1 |
| Liu, P | 2 |
| He, XH | 2 |
| Nakayama-Ichiyama, S | 2 |
| Yokote, T | 2 |
| Oka, S | 2 |
| Takubo, T | 2 |
| Tsuji, M | 2 |
| Hanafusa, T | 2 |
| Iwaki, K | 1 |
| Kobayashi, K | 1 |
| Akioka, T | 1 |
| Hiraoka, N | 1 |
| Takayama, A | 1 |
| Yung, L | 1 |
| Maclennan, K | 1 |
| Hancock, B | 1 |
| Hoskin, P | 1 |
| Qian, W | 1 |
| Boesen, AM | 1 |
| Grigg, A | 2 |
| Browett, P | 1 |
| Trneny, M | 1 |
| Jonak, C | 1 |
| Troch, M | 1 |
| Müllauer, L | 1 |
| Niederle, B | 1 |
| Hoffmann, M | 1 |
| Raderer, M | 1 |
| Cunningham, S | 1 |
| Muneer, S | 1 |
| Ranganathan, A | 1 |
| Shrader, M | 1 |
| Hainsworth, JD | 2 |
| Flinn, IW | 1 |
| Spigel, DR | 1 |
| Clark, BL | 1 |
| Griner, PL | 1 |
| Vazquez, ER | 1 |
| Doss, HH | 1 |
| Shipley, D | 1 |
| Franco, LA | 1 |
| Burris, HA | 1 |
| Greco, FA | 2 |
| Kohri, M | 1 |
| Hagiwara, Y | 1 |
| Tanae, K | 1 |
| Takahashi, N | 3 |
| Bessho, M | 1 |
| Okamoto, M | 3 |
| Laatiri, MA | 1 |
| Elloumi, M | 1 |
| Ali, ZB | 1 |
| Ben Othmen, T | 1 |
| Msadek, F | 1 |
| Toumi, N | 1 |
| Bouaouina, N | 1 |
| Daoud, J | 1 |
| Maalej, M | 1 |
| Ghannem, H | 1 |
| Meddeb, B | 1 |
| Ngamphaiboon, N | 1 |
| Pukiat, S | 1 |
| Kandimalla, Y | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Rooney, JJ | 1 |
| Kiewe, P | 1 |
| Thiel, E | 1 |
| Kim, BJ | 1 |
| Park, HR | 1 |
| Roh, HJ | 1 |
| Jeong, DS | 1 |
| Park, KW | 1 |
| Cho, SC | 1 |
| So, YT | 1 |
| Reiser, M | 2 |
| Freund, M | 1 |
| Metzner, B | 1 |
| Feller, A | 1 |
| Pentheroudakis, G | 1 |
| Goussia, A | 1 |
| Voulgaris, E | 1 |
| Nikolaidis, K | 1 |
| Ioannidou, E | 1 |
| Papoudou-Bai, A | 1 |
| Grepi, K | 1 |
| Kanavaros, P | 1 |
| Pavlidis, N | 1 |
| Bai, M | 1 |
| Park, GH | 1 |
| Kim, CH | 1 |
| Chung, WK | 2 |
| Won, CH | 1 |
| Chang, SE | 1 |
| Lee, MW | 1 |
| Moon, KC | 1 |
| Higashiyama, A | 1 |
| Hashino, S | 1 |
| Onozawa, M | 1 |
| Takahata, M | 1 |
| Okada, K | 1 |
| Kahata, K | 1 |
| Taniguchi, N | 1 |
| Nasuhara, Y | 1 |
| Kubota, K | 1 |
| Fujimoto, N | 1 |
| Matsuno, Y | 2 |
| Nishimura, M | 1 |
| Asaka, M | 1 |
| Graves, TD | 1 |
| Parry, A | 1 |
| Miki, M | 2 |
| Masaki, Y | 3 |
| Nakamura, T | 2 |
| Iwao, H | 1 |
| Nakajima, A | 1 |
| Sakai, T | 2 |
| Sawaki, T | 2 |
| Kawanami, T | 1 |
| Kaito, M | 1 |
| Kurose, N | 1 |
| Fujita, Y | 1 |
| Fukushima, T | 2 |
| Hirose, Y | 1 |
| Umehara, H | 2 |
| Tamaru, J | 2 |
| Yoshino, T | 2 |
| Nakamura, S | 6 |
| Nakamine, H | 1 |
| Nishigami, T | 1 |
| Kataoka, TR | 1 |
| Torii, I | 1 |
| Sato, A | 1 |
| Tamura, K | 4 |
| Hirano, H | 1 |
| Hida, N | 1 |
| Ikeuchi, H | 1 |
| Tsujimura, T | 2 |
| Loberiza, FR | 1 |
| Arevalo, A | 1 |
| Bast, M | 1 |
| Armitage, J | 1 |
| Ahbeddou, N | 1 |
| Fetohi, M | 1 |
| Khanoussi, BE | 1 |
| Errihani, H | 1 |
| Hansen, PB | 1 |
| Al-Farra, G | 1 |
| Kinouchi, T | 1 |
| Kobayashi, M | 1 |
| Ueda, T | 1 |
| Takada, T | 1 |
| Soda, M | 2 |
| Togashi, Y | 1 |
| Ota, Y | 1 |
| Sekiguchi, Y | 2 |
| Hatano, S | 1 |
| Asaka, R | 1 |
| Noguchi, M | 2 |
| Mano, H | 1 |
| Beltran, BE | 1 |
| Castillo, JJ | 1 |
| Salas, R | 1 |
| Quiñones, P | 1 |
| Morales, D | 1 |
| Cotrina, E | 1 |
| Miranda, RN | 1 |
| Sotomayor, EM | 1 |
| Lim, Y | 1 |
| Kim, TY | 1 |
| Choi, IS | 1 |
| Lee, TS | 1 |
| Kim, JE | 1 |
| Chang, MS | 1 |
| Kim, KH | 2 |
| Ohnishi, S | 1 |
| Onishi, R | 1 |
| Suzuki, M | 1 |
| Kubo, K | 2 |
| Dazai, M | 1 |
| Yamamoto, J | 1 |
| Oda, H | 1 |
| Tada, K | 1 |
| Miyagishima, T | 1 |
| Hosokai, R | 1 |
| Imai, C | 1 |
| Takachi, T | 1 |
| Iwabuchi, H | 1 |
| Imamura, M | 1 |
| Uchiyama, M | 1 |
| Shin, SH | 1 |
| Im, H | 1 |
| Ye, BJ | 1 |
| Song, MK | 2 |
| Lee, SM | 1 |
| Kim, YS | 1 |
| Min, JJ | 1 |
| Song, HC | 1 |
| Jeong, YY | 1 |
| Bae, SY | 1 |
| Ahn, JS | 2 |
| Kim, YK | 2 |
| Bom, HS | 1 |
| Chung, IJ | 2 |
| Lee, JJ | 3 |
| Dyer, MJ | 1 |
| Ye, H | 1 |
| Isaacson, PG | 1 |
| Neri, N | 2 |
| Jesús Nambo, M | 1 |
| Avilés, A | 2 |
| Schipper, EM | 1 |
| Posthuma, W | 1 |
| Snieders, I | 1 |
| Brouwer, RE | 1 |
| Herrmann, K | 1 |
| Buck, AK | 1 |
| Schuster, T | 1 |
| Junger, A | 1 |
| Wieder, HA | 1 |
| Graf, N | 1 |
| Ringshausen, I | 1 |
| Rudelius, M | 1 |
| Wester, HJ | 1 |
| Schwaiger, M | 1 |
| Keller, U | 1 |
| Dechow, T | 1 |
| Mizutani, T | 1 |
| Shimada, K | 2 |
| Heuberger, BM | 1 |
| Weiler, D | 1 |
| Bussmann, C | 1 |
| Kuttenberger, JJ | 1 |
| Marcheselli, L | 1 |
| Marcheselli, R | 1 |
| Bari, A | 1 |
| Liardo, EV | 1 |
| Morabito, F | 1 |
| Baldini, L | 1 |
| Brugiatelli, M | 1 |
| Merli, F | 1 |
| Di Renzo, N | 1 |
| Sacchi, S | 1 |
| Micallef, IN | 1 |
| Maurer, MJ | 1 |
| Wiseman, GA | 1 |
| Nikcevich, DA | 1 |
| Kurtin, PJ | 1 |
| Cannon, MW | 1 |
| Perez, DG | 1 |
| Soori, GS | 1 |
| Link, BK | 1 |
| Habermann, TM | 1 |
| Witzig, TE | 1 |
| Hong, J | 1 |
| Park, S | 1 |
| Park, J | 1 |
| Kim, HS | 1 |
| Ahn, JY | 1 |
| Rim, MY | 1 |
| Jung, M | 1 |
| Sym, SJ | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Nguyen, TT | 1 |
| Gubens, M | 1 |
| Arber, DA | 1 |
| Juretzka, M | 1 |
| Aziz, N | 1 |
| Wang, Q | 1 |
| Cao, X | 1 |
| Jiang, J | 1 |
| Wang, T | 1 |
| Jin, MS | 1 |
| Hasselblom, S | 1 |
| Stenson, M | 1 |
| Werlenius, O | 1 |
| Sender, M | 1 |
| Lewerin, C | 1 |
| Hansson, U | 1 |
| Nilsson-Ehle, H | 1 |
| Andersson, PO | 1 |
| Ogata-Suetsugu, S | 1 |
| Maeyama, T | 1 |
| Takeshita, M | 1 |
| Hamada, N | 1 |
| Takayama, K | 1 |
| Nakanishi, Y | 1 |
| Tsunoda, S | 2 |
| Inoue, K | 2 |
| Izumi, T | 1 |
| Yamamoto, T | 1 |
| Hoshi, S | 1 |
| Hirabayashi, K | 1 |
| Igarashi, S | 1 |
| Akutsu, M | 1 |
| Kano, Y | 1 |
| Upanal, N | 1 |
| Enjeti, A | 1 |
| Iqbal, J | 1 |
| Meyer, PN | 1 |
| Johnson, NA | 1 |
| Connors, JM | 2 |
| Jaffe, E | 1 |
| Cook, JR | 1 |
| Tubbs, RR | 1 |
| Takashima, M | 1 |
| Saito, H | 1 |
| Misaki, S | 1 |
| Onishi, Y | 2 |
| Kasugai, T | 1 |
| Akuta, K | 1 |
| Doi, Y | 1 |
| Ujiie, H | 1 |
| Sugahara, H | 1 |
| Hoshida, Y | 1 |
| Sakoda, H | 1 |
| Tadmor, T | 1 |
| Bejar, J | 1 |
| Attias, D | 1 |
| Polliack, A | 1 |
| Chung, JS | 3 |
| Yamamoto, W | 1 |
| Shimazu, Y | 1 |
| Murayama, K | 1 |
| Yano, T | 1 |
| Okamoto, R | 1 |
| Kikuchi, A | 1 |
| Sato, K | 2 |
| Sunami, K | 1 |
| Shibayama, H | 1 |
| Takimoto, R | 1 |
| Ohshima, R | 1 |
| Hatta, Y | 1 |
| Moriuchi, Y | 1 |
| Yamamoto, M | 2 |
| Numata, A | 1 |
| Kado, H | 1 |
| Hatta, T | 1 |
| Ueno, R | 1 |
| Takagi, A | 1 |
| Segawa, H | 1 |
| Sawada, K | 1 |
| Hosokawa, Y | 1 |
| Johnsen, HE | 1 |
| Lugtenburg, PJ | 1 |
| Salar, A | 1 |
| Pettengell, R | 1 |
| Rossi, FG | 1 |
| Verhoef, G | 1 |
| Schwenkglenks, M | 1 |
| Bendall, K | 1 |
| Duehrsen, U | 1 |
| Laurent, G | 1 |
| Morschhauser, F | 1 |
| Ghesquières, H | 1 |
| Bologna, S | 1 |
| Fruchart, C | 1 |
| Corront, B | 1 |
| Gabarre, J | 1 |
| Bonnet, C | 1 |
| Janvier, M | 1 |
| Chen, LP | 1 |
| Lin, SJ | 1 |
| Yu, MS | 1 |
| Kim, SK | 1 |
| Choe, S | 1 |
| Cho, GJ | 1 |
| Vassilakopoulos, TP | 1 |
| Pangalis, GA | 1 |
| Katsigiannis, A | 1 |
| Papageorgiou, SG | 1 |
| Constantinou, N | 1 |
| Terpos, E | 1 |
| Zorbala, A | 1 |
| Vrakidou, E | 1 |
| Repoussis, P | 1 |
| Poziopoulos, C | 1 |
| Galani, Z | 1 |
| Dimopoulou, MN | 1 |
| Kokoris, SI | 1 |
| Sachanas, S | 1 |
| Kalpadakis, C | 1 |
| Dimitriadou, EM | 1 |
| Siakantaris, MP | 1 |
| Kyrtsonis, MC | 1 |
| Dervenoulas, J | 2 |
| Dimopoulos, MA | 1 |
| Meletis, J | 1 |
| Roussou, P | 1 |
| Panayiotidis, P | 1 |
| Beris, P | 1 |
| Angelopoulou, MK | 1 |
| Freeman, HJ | 1 |
| Kwan, PW | 1 |
| Webber, D | 1 |
| Podjasek, JO | 1 |
| Camilleri, MJ | 1 |
| Muta, T | 1 |
| Nakaike, T | 1 |
| Fujisaki, T | 1 |
| Shiraishi, T | 1 |
| Lin, TL | 1 |
| Kuo, MC | 1 |
| Shih, LY | 1 |
| Dunn, P | 1 |
| Wang, PN | 1 |
| Wu, JH | 1 |
| Tang, TC | 1 |
| Chang, H | 1 |
| Hung, YS | 1 |
| Olivieri, A | 1 |
| Gini, G | 1 |
| Bocci, C | 1 |
| Montanari, M | 1 |
| Trappolini, S | 1 |
| Olivieri, J | 1 |
| Brunori, M | 1 |
| Catarini, M | 1 |
| Guiducci, B | 1 |
| Isidori, A | 1 |
| Alesiani, F | 1 |
| Giuliodori, L | 1 |
| Marcellini, M | 1 |
| Visani, G | 1 |
| Poloni, A | 1 |
| Leoni, P | 1 |
| Nasu, K | 2 |
| Nishida, M | 1 |
| Takai, N | 1 |
| Narahara, H | 1 |
| Hassan, U | 1 |
| Mushtaq, S | 1 |
| Mamoon, N | 1 |
| Asghar, AH | 1 |
| Ishtiaq, S | 1 |
| Liu, YC | 1 |
| Chang, WL | 1 |
| Gau, JP | 1 |
| Chao, TC | 1 |
| Hemmaway, CJ | 1 |
| Danga, A | 1 |
| Igbokwe, U | 1 |
| Radunovic, A | 1 |
| Watanabe, M | 1 |
| Satoi, H | 1 |
| Nishida, N | 1 |
| Toda, H | 1 |
| Matsumoto, S | 1 |
| Kendall, KM | 1 |
| Thomas, RH | 1 |
| Corkill, RG | 1 |
| Robertson, NP | 1 |
| Huang, YH | 1 |
| Qin, Y | 1 |
| Lü, Z | 1 |
| Dong, M | 1 |
| Zhang, CG | 1 |
| Yang, JL | 1 |
| Sakaguchi, T | 1 |
| Nishi, H | 1 |
| Miyagawa, S | 1 |
| Yoshikawa, Y | 1 |
| Yamauchi, T | 1 |
| Fukushima, S | 1 |
| Saito, S | 3 |
| Sawa, Y | 1 |
| Bruneau, O | 1 |
| Le Moigne, F | 1 |
| Guyotat, J | 1 |
| Nicolas-Virelizier, E | 1 |
| Guilloton, L | 1 |
| Drouet, A | 1 |
| Nawa, Y | 2 |
| Miyagawa, M | 1 |
| Nakase, K | 1 |
| Hara, M | 1 |
| Huang, HC | 1 |
| Cheng, AL | 1 |
| Lin, CW | 1 |
| Kuo, SH | 1 |
| Machida, H | 1 |
| Shinohara, T | 1 |
| Hatakeyama, N | 1 |
| Okano, Y | 1 |
| Nakano, M | 1 |
| Tobiume, M | 1 |
| Naruse, K | 1 |
| Iwahara, Y | 1 |
| Ogushi, F | 1 |
| Shimada, A | 1 |
| Imai, H | 1 |
| Wakabayashi, M | 1 |
| Komatsu, N | 1 |
| Gawryluk, D | 1 |
| Słodkowska, J | 1 |
| Dobkowski, P | 1 |
| Wiatr, E | 1 |
| Hock, LM | 1 |
| Lynch, JC | 1 |
| Aoun, P | 1 |
| Gisselbrecht, C | 1 |
| Emile, JF | 1 |
| Lederlin, P | 1 |
| Sebban, C | 1 |
| Morel, P | 2 |
| Bouabdallah, R | 1 |
| Reyes, F | 1 |
| Takauchi, K | 1 |
| Kono, H | 1 |
| Ito, T | 1 |
| Zaima, K | 1 |
| Okumoto, S | 1 |
| Kawakami, K | 1 |
| Kadowaki, S | 1 |
| Wunderlich, A | 1 |
| Kloess, M | 1 |
| Rudolph, C | 1 |
| Truemper, L | 1 |
| Bittner, S | 1 |
| Schmalenberg, H | 1 |
| Schmits, R | 1 |
| Oshiro, A | 1 |
| Nagasaki, A | 1 |
| Nakachi, A | 1 |
| Uchima, N | 1 |
| Hasegawa, H | 1 |
| Nakamoto, M | 1 |
| Kinjo, N | 1 |
| Kinjo, F | 1 |
| Taira, N | 1 |
| Masuda, M | 1 |
| Takasu, N | 1 |
| GRODEN, BM | 1 |
| DUNNIGAN, MG | 1 |
| AOKI, Y | 1 |
| KAWABE, A | 1 |
| MASHIMA, T | 1 |
| OGURO, C | 1 |
| ARDOUIN, AP | 1 |
| LIBERTI, R | 1 |
| PLATTNER, I | 1 |
| MURRAY, PJ | 1 |
| SLADDEN, RA | 1 |
| Sathiapalan, RK | 1 |
| Hainau, B | 1 |
| Al-Mane, K | 1 |
| Belgaumi, AF | 1 |
| Barutca, S | 1 |
| Kadikoylu, G | 1 |
| Bolaman, Z | 1 |
| Levi, E | 1 |
| Yavasoglu, I | 1 |
| Motegi, S | 1 |
| Nishizaki, Y | 1 |
| Muramatsu, C | 1 |
| Kobayashi, F | 1 |
| Shiozawa, H | 1 |
| Kamochi, J | 1 |
| Itakura, M | 1 |
| Shibuya, M | 1 |
| Ogawa, T | 1 |
| Matsuzaki, S | 1 |
| Arimura, K | 1 |
| Arima, N | 1 |
| Hamada, H | 1 |
| Kukita, T | 1 |
| Matsushita, K | 1 |
| Tei, C | 1 |
| Shibata, H | 1 |
| Aoyama, Y | 1 |
| Hasegawa, T | 1 |
| Sakamoto, C | 1 |
| Sawada, Y | 1 |
| Yabuki, D | 1 |
| Masuda, E | 1 |
| Satou, D | 1 |
| Iwasawa, T | 1 |
| Kuroda, K | 1 |
| Tajima, M | 1 |
| Matsushima, M | 1 |
| Froehner, M | 1 |
| Haase, M | 1 |
| Hakenberg, OW | 1 |
| Wirth, MP | 1 |
| Uchino, K | 1 |
| Sameshima, H | 1 |
| Miyamoto, T | 1 |
| Iino, T | 1 |
| Kato, K | 1 |
| Henzan, H | 1 |
| Nagafuji, K | 1 |
| Gondo, H | 1 |
| Harada, M | 1 |
| Gono, T | 1 |
| Shimojima, Y | 1 |
| Hoshi, K | 1 |
| Tokuda, T | 1 |
| Shikama, N | 1 |
| Matsuda, M | 1 |
| Ikeda, S | 1 |
| Miyazaki, C | 1 |
| Mukai, M | 2 |
| Kawaai, Y | 1 |
| Takeda, M | 1 |
| Katoh, N | 1 |
| Nagano, S | 1 |
| Kohno, M | 1 |
| Sekiguchi, N | 1 |
| Nishimoto, J | 1 |
| Tanimoto, K | 1 |
| Kusumoto, S | 1 |
| Asamura, H | 1 |
| Kagami, Y | 1 |
| Knight, C | 1 |
| Hind, D | 1 |
| Brewer, N | 1 |
| Abbott, V | 1 |
| Nagashima, O | 1 |
| Takahashi, K | 1 |
| Suzuki, T | 3 |
| Fukuchi, Y | 1 |
| Isobe, Y | 1 |
| Oshimi, K | 1 |
| Schneider, T | 1 |
| Tóth, E | 1 |
| Molnár, Z | 1 |
| Várady, E | 1 |
| Deák, B | 1 |
| Horváth, A | 1 |
| Horváth, GI | 1 |
| Eid, H | 1 |
| Schneider, K | 1 |
| Lovey, J | 1 |
| Keresztes, S | 1 |
| Esik, O | 1 |
| Lengyel, Z | 1 |
| Rosta, A | 1 |
| Fu, TY | 1 |
| Wang, JS | 1 |
| Tseng, HH | 1 |
| Tang, S | 1 |
| Lai, KN | 1 |
| Ohkubo, H | 1 |
| Takaku, T | 1 |
| Katagiri, T | 1 |
| Paku, J | 1 |
| Kasuga, I | 1 |
| Minemura, K | 1 |
| Gotoh, A | 1 |
| Serizawa, H | 2 |
| Suekane, H | 1 |
| Matsumoto, H | 1 |
| Esaki, M | 1 |
| Yao, T | 2 |
| Iida, M | 2 |
| Burton, C | 1 |
| Uner, A | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Unsal, D | 1 |
| Miyahara, T | 1 |
| Oyabul, Y | 1 |
| Hayashi, T | 2 |
| Shimizu, S | 1 |
| Matsuoka, K | 1 |
| Delgado, S | 1 |
| Pérez, F | 1 |
| Nambo, MJ | 1 |
| Cleto, S | 1 |
| Talavera, A | 1 |
| Huerta-Guzmán, J | 1 |
| Takenaka, S | 1 |
| Mitsudo, K | 1 |
| Goto, T | 1 |
| Kadota, K | 1 |
| Fujii, S | 1 |
| Yamamoto, H | 1 |
| Fuku, Y | 1 |
| Hirono, A | 1 |
| Taba, M | 1 |
| Ikeda, A | 1 |
| Kojima, Y | 2 |
| Maekawa, J | 1 |
| Maekawa, S | 1 |
| Saeki, H | 1 |
| Oonishi, T | 1 |
| Ueda, N | 1 |
| Lin, TY | 1 |
| Zhang, HY | 1 |
| Huang, Y | 1 |
| Guan, ZZ | 1 |
| Shen, T | 1 |
| Ke, XY | 1 |
| Wang, HQ | 1 |
| Shen, ZX | 1 |
| Yu, SY | 1 |
| Liu, T | 1 |
| Shi, XL | 1 |
| Otrock, ZK | 1 |
| Shamseddine, AI | 1 |
| Taher, AT | 1 |
| Kanamori, H | 1 |
| Saio, M | 1 |
| Tomita, E | 1 |
| Yoshino, S | 1 |
| Konomi, H | 1 |
| Hirahashi, M | 1 |
| Shirao, S | 1 |
| Kuroda, H | 1 |
| Kida, M | 1 |
| Watanabe, H | 1 |
| Matsunaga, T | 1 |
| Niitsu, Y | 1 |
| Konuma, Y | 1 |
| Hirayama, Y | 1 |
| Kohda, K | 1 |
| Avanzi, GC | 1 |
| Castello, L | 1 |
| Sainaghi, PP | 1 |
| Bergamasco, L | 1 |
| Boldorini, R | 1 |
| Bartoli, E | 1 |
| Kikukawa, M | 1 |
| Kiuchi, A | 1 |
| Abe, S | 1 |
| Fujii, H | 1 |
| Kanaya, K | 1 |
| Shin, K | 1 |
| Iwamoto, T | 1 |
| Lin, M | 1 |
| Saunders, CA | 1 |
| Ho Shon, IA | 1 |
| Estell, J | 1 |
| Howlin, K | 1 |
| Lee, V | 1 |
| Lin, P | 1 |
| Laack, NN | 1 |
| Ballman, KV | 1 |
| Brown, PB | 1 |
| O'Neill, BP | 1 |
| Goto, A | 1 |
| Yamamoto, S | 1 |
| Notoya, A | 1 |
| Takada, A | 1 |
| Lee, J | 1 |
| Kim, K | 1 |
| Jung, CW | 1 |
| Lim, HY | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Ko, YH | 1 |
| Kim, YH | 1 |
| Park, C | 1 |
| Yoon, SH | 1 |
| Lee, WY | 1 |
| Chun, HK | 1 |
| Bouzani, M | 1 |
| Karmiris, T | 1 |
| Rontogianni, D | 2 |
| Delimpassi, S | 1 |
| Apostolidis, J | 1 |
| Mpakiri, M | 1 |
| Nikiforakis, E | 1 |
| Odawara, J | 1 |
| Asada, N | 1 |
| Aoki, T | 1 |
| Yamakura, M | 1 |
| Ohuchi, T | 1 |
| Matsue, K | 1 |
| Matano, S | 1 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Gurbuxani, S | 1 |
| Anastasi, J | 1 |
| Rimsza, LM | 1 |
| Farinha, P | 1 |
| Fuchs, DA | 1 |
| Masoudi, H | 1 |
| Yamaguchi, T | 1 |
| Kagawa, R | 1 |
| Takeda, R | 1 |
| Sakata, S | 1 |
| Nishizaki, D | 1 |
| Takamatsu, T | 1 |
| Iwasa, Y | 1 |
| Kim, DH | 1 |
| Baek, JH | 1 |
| Chae, YS | 1 |
| Park, YH | 1 |
| Song, HS | 1 |
| Sohn, SK | 1 |
| Saito, B | 1 |
| Shiozawa, E | 1 |
| Usui, T | 1 |
| Nakashima, H | 1 |
| Maeda, T | 1 |
| Hattori, N | 2 |
| Shimozuma, J | 1 |
| Adachi, D | 1 |
| Yamochi-Onizuka, T | 1 |
| Takimoto, M | 1 |
| Nakamaki, T | 1 |
| Ota, H | 1 |
| Tomoyasu, S | 1 |
| Sumi, M | 2 |
| Ichikawa, N | 2 |
| Shimizu, I | 2 |
| Yotsumoto, M | 2 |
| Ueno, M | 2 |
| Kobayashi, H | 2 |
| Brieva, J | 1 |
| Yoshimura, J | 1 |
| Kato, S | 1 |
| Tamaki, K | 1 |
| Kohno, K | 1 |
| Kaneyuki, U | 1 |
| Maeda, M | 1 |
| Saikusa-Itoh, Y | 1 |
| Hayashida, A | 1 |
| Iida, S | 1 |
| Suefuji, H | 1 |
| Okuda, S | 1 |
| Solomonov, A | 1 |
| Zuckerman, T | 1 |
| Goralnik, L | 1 |
| Ben-Arieh, Y | 1 |
| Rowe, JM | 1 |
| Yigla, M | 1 |
| Ngo, L | 1 |
| Hee, SW | 1 |
| Lim, LC | 1 |
| Tao, M | 1 |
| Quek, R | 1 |
| Yap, SP | 1 |
| Loong, EL | 1 |
| Sng, I | 1 |
| Hwan-Cheong, TL | 1 |
| Ang, MK | 1 |
| Ngeow, J | 1 |
| Tham, CK | 1 |
| Tan, MH | 1 |
| Lim, ST | 1 |
| Tsurusawa, M | 2 |
| Taga, T | 2 |
| Horikoshi, Y | 2 |
| Ogawa, A | 1 |
| Kikuta, A | 1 |
| Kanegane, H | 1 |
| Matsushita, T | 1 |
| Hyakuna, N | 1 |
| Shimomura, Y | 1 |
| Mitchell, PL | 1 |
| Marlton, P | 1 |
| Seymour, JF | 1 |
| Hertzberg, M | 1 |
| Enno, A | 1 |
| Herrmann, R | 1 |
| Bond, R | 1 |
| Arthur, C | 1 |
| Chen, WL | 1 |
| Ho, CL | 1 |
| Johnson, GJ | 1 |
| Costello, WG | 1 |
| Oken, MM | 1 |
| Sponzo, RW | 1 |
| Barnes, JM | 1 |
| Ezdinli, EZ | 1 |
| Bennett, JM | 1 |
| Silverstein, MN | 1 |
| Glick, JH | 1 |
| Berard, CW | 1 |
| Kondrat'eva, NA | 1 |
| Lorie, IuI | 1 |
| Kruglova, GV | 1 |
| Vorob'ev, AI | 1 |
| Brilliant, MD | 1 |
| Blackledge, G | 1 |
| Bush, H | 1 |
| Crowther, D | 1 |
| Deakin, DP | 1 |
| Dodge, OG | 1 |
| Garrett, JV | 1 |
| Palmer, M | 1 |
| Pearson, D | 1 |
| Scarffe, JH | 1 |
| Todd, ID | 1 |
| Wilkinson, PM | 1 |
| Dupriez, B | 1 |
| Herbrecht, R | 1 |
| Bastion, Y | 1 |
| Delannoy, A | 1 |
| Nouvel, C | 1 |
| Bouabdallah, K | 1 |
| Baumelou, E | 1 |
| Lishner, M | 1 |
| Slingerland, J | 1 |
| Theresa, C | 1 |
| Sutcliffe, SB | 1 |
| Santana, VM | 1 |
| Abromowitch, M | 1 |
| Sandlund, JT | 1 |
| Behm, FG | 1 |
| Ayers, GD | 1 |
| Roberson, PK | 1 |
| Pui, CH | 1 |
| Hayashi, K | 2 |
| Ohnoshi, T | 2 |
| Kawashima, K | 2 |
| Matsutomo, S | 2 |
| Tagawa, S | 2 |
| Mizuta, J | 2 |
| Tada, A | 2 |
| Ueno, K | 2 |
| Kimura, I | 1 |
| Waits, TM | 1 |
| Greer, JP | 1 |
| Graziano, F | 1 |
| Cellerino, R | 1 |
| Menestrina, F | 1 |
| Nicoli, N | 1 |
| Gramazio, A | 1 |
| Latini, L | 1 |
| Piga, A | 1 |
| Miyake, O | 1 |
| Tsujihata, M | 1 |
| Itoh, H | 3 |
| Wakatsuki, A | 1 |
| Itatani, H | 2 |
| Morozumi, M | 1 |
| Takasu, H | 1 |
| Okada, M | 2 |
| Suwa, Y | 1 |
| Noguchi, S | 1 |
| Sakuramoto, T | 1 |
| Shuin, T | 1 |
| Kinoshita, Y | 1 |
| Hosaka, M | 1 |
| Rosenthal, MA | 1 |
| Sheridan, WP | 1 |
| Green, MD | 1 |
| Liew, K | 1 |
| Fox, RM | 1 |
| Hirokawa, M | 2 |
| Lee, M | 1 |
| Motegi, M | 1 |
| Miura, AB | 2 |
| Soslow, RA | 1 |
| Davis, RE | 1 |
| Warnke, RA | 2 |
| Cleary, ML | 1 |
| Kamel, OW | 1 |
| Vaughan Hudson, B | 1 |
| Hancock, BW | 3 |
| Hoskin, PJ | 2 |
| Cunningham, DC | 2 |
| Newland, AC | 2 |
| Milligan, DW | 1 |
| Stevenson, PA | 2 |
| Wood, JK | 2 |
| MacLennan, KA | 2 |
| Anderson, L | 1 |
| Gregory, WM | 2 |
| Vaughan Hudson, G | 1 |
| Hattenhauer, MG | 1 |
| Pach, JM | 1 |
| Norman, RA | 1 |
| Liberman, RB | 1 |
| Przyjemski, C | 1 |
| Girshovich, L | 1 |
| Yoshikawa, I | 1 |
| Murata, I | 1 |
| Tanaka, Y | 1 |
| Kanagawa, K | 1 |
| Tabaru, A | 1 |
| Otsuki, M | 1 |
| Ono, K | 1 |
| Matsumura, S | 1 |
| Sakamoto, K | 1 |
| Kobayashi, S | 1 |
| Kamano, T | 1 |
| Iwasaki, R | 1 |
| Satoh, T | 1 |
| Tsushima, K | 1 |
| Hizawa, Y | 1 |
| Nakui, Y | 1 |
| Itoh, J | 1 |
| Tamura, Y | 1 |
| Saitoh, S | 1 |
| Taka-mi, H | 1 |
| Munakata, A | 1 |
| Hasegawa, Y | 1 |
| Ninomiya, H | 1 |
| Kamoshita, M | 1 |
| Ohtani, K | 1 |
| Kobayashi, T | 2 |
| Kojima, H | 1 |
| Nagasawa, T | 1 |
| Oyama, H | 1 |
| Yamao, K | 1 |
| Sugiyama, T | 1 |
| Matsuura, O | 1 |
| Murakami, S | 1 |
| Ikeda, K | 1 |
| Inoue, S | 1 |
| Kawabata, Y | 1 |
| Horiuchi, T | 1 |
| Hatakeyama, T | 1 |
| Kume, M | 2 |
| Nimura, T | 1 |
| Nishinari, T | 1 |
| Hausmaninger, H | 1 |
| Oppitz, P | 1 |
| Stöger, M | 1 |
| Klocker, J | 1 |
| Neubauer, M | 1 |
| Helm, W | 1 |
| Pont, J | 1 |
| Fazeny, B | 1 |
| Hudec, M | 1 |
| Simonitsch, I | 1 |
| Radaszkiewicz, T | 1 |
| Biswal, BM | 1 |
| Sharma, A | 1 |
| Sharma, MC | 1 |
| Prasad, RR | 1 |
| Roy, K | 1 |
| Rath, GK | 1 |
| Nonaka, Y | 1 |
| Nomura, T | 1 |
| Ogawa, M | 1 |
| Mori, S | 1 |
| Kajiura, Y | 1 |
| Ogoshi, K | 1 |
| Nakamura, K | 2 |
| Miyaji, M | 1 |
| Kondo, Y | 1 |
| Makuuchi, H | 1 |
| Tajima, T | 1 |
| Oobayashi, Y | 1 |
| Masumoto, A | 1 |
| Horiki, T | 1 |
| Ueyama, H | 1 |
| Kumamoto, T | 1 |
| Johno, M | 1 |
| Mita, S | 1 |
| Tsuda, T | 1 |
| Inatomi, Y | 1 |
| Inoue, T | 1 |
| Nagata, S | 1 |
| Matsuno, H | 1 |
| Itoh, Y | 1 |
| Yoshimatsu, J | 1 |
| Urata, K | 1 |
| Miyakawa, I | 1 |
| Usami, T | 1 |
| Ushiyama, T | 1 |
| Fujita, K | 1 |
| Bloor, AJ | 1 |
| Seale, JR | 1 |
| Marcus, RE | 1 |
| Yazici, H | 1 |
| Saip, P | 1 |
| Inanç, S | 1 |
| Onat, H | 1 |
| Dalay, N | 1 |
| Katano, N | 1 |
| Hirota, T | 1 |
| Ito, M | 1 |
| Yanase, T | 1 |
| Asami, K | 1 |
| Koizumi, S | 1 |
| Nakayama, M | 1 |
| Miyawaki, T | 1 |
| Suzumiya, J | 2 |
| Nishikawa, K | 1 |
| Mugisima, H | 1 |
| Hatae, Y | 1 |
| Iwai, A | 1 |
| Anami, K | 1 |
| Osima, K | 1 |
| Kaneko, Y | 1 |
| Kataoka, S | 1 |
| Tanaka, A | 1 |
| Chin, M | 1 |
| Watanabe, A | 1 |
| Fujimoto, T | 1 |
| Gumà, J | 1 |
| Rubió, J | 1 |
| Masip, C | 1 |
| Alvaro, T | 1 |
| Borràs, JL | 1 |
| Troussard, X | 1 |
| Mossafa, H | 1 |
| Salaün, V | 1 |
| Nagatsuma, K | 1 |
| Tanomogi, H | 1 |
| Hasegawa, S | 2 |
| Shimizu, K | 1 |
| Hertzberg, MS | 1 |
| Schifter, M | 1 |
| Sullivan, J | 1 |
| Stapleton, K | 1 |
| Milligan, D | 1 |
| Vaughan, B | 1 |
| Vaughan, G | 1 |
| Lee, DH | 1 |
| Park, JH | 1 |
| Chung, DJ | 1 |
| Chung, MY | 1 |
| Lee, TH | 1 |
| Munakata, S | 1 |
| Hirano, S | 1 |
| Yoshiyama, Y | 1 |
| Koizumi, M | 1 |
| Kobayasi, T | 1 |
| Hattori, T | 1 |
| Kanda, M | 1 |
| Kumagawa, M | 1 |
| Nagano, M | 1 |
| Hirata, M | 1 |
| Mohammad, RM | 1 |
| Wall, NR | 1 |
| Dutcher, JA | 1 |
| Al-Katib, AM | 1 |
| Matsuda, T | 1 |
| Okihama, Y | 1 |
| Egami, K | 1 |
| Wada, M | 1 |
| Yoshioka, M | 1 |
| Maeda, S | 1 |
| Onda, M | 1 |
| Shimamoto, T | 1 |
| Hayashi, S | 1 |
| Ando, K | 1 |
| Yguchi, M | 1 |
| Miyazawa, K | 1 |
| Kimura, Y | 1 |
| Matoba-Ueno, K | 1 |
| Fujimoto, S | 1 |
| Doi, N | 1 |
| Nishino, T | 1 |
| Yamano, S | 1 |
| Shiiki, H | 1 |
| Hashimoto, T | 1 |
| Hirayama, K | 1 |
| Fukazawa, A | 1 |
| Ohata, K | 1 |
| Sunayama, K | 1 |
| Kashiwabara, H | 1 |
| Maruyama, K | 1 |
| Konno, H | 1 |
| Miura, K | 1 |
| Laver, JH | 1 |
| Mahmoud, H | 1 |
| Pick, TE | 1 |
| Hutchinson, RE | 1 |
| Weinstein, HJ | 1 |
| Schwenn, M | 1 |
| Weitzman, S | 1 |
| Murphy, SB | 1 |
| Ochoa, S | 1 |
| Shuster, JJ | 2 |
| Tsirigotis, P | 1 |
| Economopoulos, T | 1 |
| Papageorgiou, E | 1 |
| Bollas, G | 1 |
| Mantzios, G | 1 |
| Kalantzis, D | 1 |
| Koumarianou, A | 1 |
| Raptis, S | 1 |
| Vitolo, U | 2 |
| Botto, B | 1 |
| Capello, D | 1 |
| Vivenza, D | 1 |
| Zagonel, V | 1 |
| Gloghini, A | 1 |
| Novero, D | 1 |
| Parvis, G | 1 |
| Calvi, R | 1 |
| Ariatti, C | 1 |
| Milan, I | 1 |
| Bertini, M | 2 |
| Boccomini, C | 1 |
| Freilone, R | 1 |
| Pregno, P | 1 |
| Orsucci, L | 1 |
| Palestro, G | 1 |
| Saglio, G | 1 |
| Carbone, A | 1 |
| Gallo, E | 1 |
| Gaidano, G | 1 |
| Okamoto, T | 1 |
| Wakae, T | 1 |
| Mori, A | 1 |
| Takatsuka, H | 1 |
| Kakishita, E | 1 |
| Yanagiya, N | 1 |
| Nakae, H | 1 |
| Chubachi, A | 1 |
| Miura, I | 1 |
| Kornacker, M | 1 |
| Kraemer, A | 1 |
| Leo, E | 1 |
| Okumoto, T | 1 |
| Tomiyama, K | 1 |
| Ino, H | 1 |
| Kanaya, Y | 1 |
| Maruyama, S | 1 |
| Otani, J | 1 |
| Yokoyama, N | 1 |
| Watanabe, I | 1 |
| Sakai, I | 1 |
| Fujita, S | 1 |
| Naysmith, A | 1 |
| Cullen, DR | 1 |
| Richmond, J | 1 |
| Wilde, CE | 1 |
| Klener, P | 1 |
| Donner, L | 1 |
| Tigges, FJ | 1 |
| Schmülling, RM | 1 |
| Hiller, E | 1 |
| Waller, HD | 1 |
| Wilms, K | 1 |
| Mattsson, W | 1 |
| von Eyben, F | 1 |
| Turesson, I | 1 |
| Wählby, S | 1 |
| Landberg, TG | 1 |
| Håkansson, LG | 1 |
| Möller, TR | 1 |
| Mattsson, WK | 1 |
| Landys, KE | 1 |
| Johansson, BG | 1 |
| Killander, DC | 1 |
| Molin, BF | 1 |
| Westling, PF | 1 |
| Lenner, PH | 1 |
| Dahl, OG | 1 |
| Cooper, DL | 1 |
| Ginsberg, SS | 1 |
| Kumagai, T | 1 |
| Abe, K | 1 |
| Enomoto, K | 1 |
| Maebou, A | 1 |
| Hara, H | 1 |
| Yoshimoto, T | 1 |
| Hirao, F | 1 |
| Sano, F | 1 |
| Koike, M | 1 |
| Wakayama, T | 1 |
| Kunika, N | 1 |
| Kubomatsu, Y | 1 |
| Katoh, M | 1 |
| Chisa, M | 1 |
| Takahashi, M | 1 |
| Utsunomiya, M | 1 |
| Takatera, H | 1 |
| Kwak, LW | 1 |
| Wilson, M | 1 |
| Weiss, LM | 1 |
| Doggett, R | 1 |
| Dorfman, RF | 1 |
| Horning, SJ | 1 |
| Resegotti, L | 1 |
| Brusamolino, E | 1 |
| Comotti, B | 1 |
| Tarella, C | 1 |
| Todeschini, G | 1 |
| Aglietta, M | 1 |
| Barbui, T | 1 |
| Bernasconi, C | 1 |
| Saha, PK | 1 |
| Sakai, H | 1 |
| Nomata, K | 1 |
| Minami, Y | 1 |
| Kanetake, H | 1 |
| Saito, Y | 1 |
| Hvizdala, EV | 1 |
| Berard, C | 1 |
| Callihan, T | 1 |
| Falletta, J | 1 |
| Sabio, H | 1 |
| Sullivan, M | 1 |
| Wharam, MD | 1 |
| Sato, M | 1 |
| Haruyama, S | 1 |
| Aono, G | 1 |
| Ohara, T | 1 |
| Ando, Y | 1 |
| Abe, R | 1 |
| Nozawa, Y | 1 |
| Wakasa, H | 1 |
| Burrow, JN | 1 |
| Wright, J | 1 |
| Juttner, CA | 1 |
| Crowley, KS | 1 |
| Kimber, RJ | 1 |
| Trepel, F | 2 |
| Stockhusen, G | 2 |
| Rastetter, J | 2 |
| Begemann, H | 1 |
| Theml, H | 1 |
| Takatani, O | 1 |
| Kimura, K | 1 |
| Birkeland, SA | 1 |
| Kemp, E | 1 |
| Miller, G | 1 |
| Coope, D | 1 |
| Garwicz, S | 1 |
| Landberg, T | 1 |
| Akerman, M | 1 |
| Stojcevski, T | 1 |
| Hallauer, W | 1 |
| Schirmeister, J | 1 |
| Oehlert, W | 1 |
| Datsenko, SF | 1 |
| Abelson, HT | 1 |
| Rabstein, LS | 1 |
| Garrett, MJ | 1 |
| Glazebrook, GA | 1 |
| el-Akkad, SM | 1 |
| Shakir, MA | 1 |
| Hall, TC | 1 |
| Choi, OS | 1 |
| Abadi, A | 1 |
| Krant, MJ | 1 |
| Schrek, R | 1 |
| Elrod, LM | 1 |
| Batra, KV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy[NCT00971763] | Phase 2 | 62 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.[NCT00140595] | Phase 3 | 380 participants (Anticipated) | Interventional | 2003-12-31 | Completed | ||
| Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma[NCT03018626] | Phase 3 | 402 participants (Anticipated) | Interventional | 2017-07-27 | Recruiting | ||
| A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00529503] | Phase 2 | 151 participants (Actual) | Interventional | 2007-09-30 | Terminated | ||
| A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma[NCT03016000] | Phase 3 | 226 participants (Anticipated) | Interventional | 2017-07-26 | Recruiting | ||
| Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized Aggressive Histologies of Non-Hodgkin's Lymphoma[NCT00005089] | Phase 2 | 71 participants (Actual) | Interventional | 2000-04-30 | Completed | ||
| First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP: a Randomized, Open, Multicenter Clinical Study[NCT05280626] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-03-25 | Not yet recruiting | ||
| A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma[NCT00193479] | Phase 2 | 51 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma[NCT00301821] | Phase 2 | 107 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Phase II Study of 90Y-ibritumomab Tiuxetan Treatment as a Consolidation After 6th R-CHOP Chemotherapy in Patients With Limited-stage, Bulky Diffuse Large B Cell Lymphoma[NCT01157988] | Phase 2 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| A Phase II Trial of Irinotecan in Recurrent Glioma[NCT00003134] | Phase 2 | 64 participants (Actual) | Interventional | 1998-01-31 | Completed | ||
| Primary Central Nervous System Non-Hodgkins's Lymphoma (PCNSL): A Phase II Clinical Trial of Radiation Therapy and High Dose Corticosteroids for Elderly Patients (70 Years of Age and Older)[NCT00003278] | Phase 2 | 28 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941] | 52 participants (Actual) | Interventional | 2005-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193479)
Timeframe: 18 Months
| Intervention | percentage of patients (Number) |
|---|---|
| CNOP (CVP)/Rituximab/Pegfilgrastim Followed by Rituximab | 81 |
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 10.5 |
The primary endpoint of the trial was the percentage of the eligible patients who were alive and event-free 12 months after enrollment to the study (EFS12). (NCT00301821)
Timeframe: From Baseline to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Epratuzumab + Rituximab + CHOP | 78 |
Overall response rate will be estimated by the number of patients with objective status of partial response (PR), unconfirmed complete response (CRu), or complete response (CR) during the first 6 cycles of treatment divided by number of evaluable patients (met eligibility criteria, signed consent form, and started treatment). Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: Baseline to first 6 cycles of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Epratuzumab + Rituximab + CHOP | 95 |
Percentage of participants alive at different time points (NCT00301821)
Timeframe: time from study entry to 36 months
| Intervention | percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Survival at 12 months | Overall Survival at 24 months | Overall Survival at 36 months | |
| Epratuzumab + Rituximab + CHOP | 89 | 81 | 80 |
Percentage of participants Progression-free at different time points. Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: the time from study entry to 36 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Progression Free Survival at 12 months | Progression Free Survival at 24 months | Progression Free Survival at 36 months | |
| Epratuzumab + Rituximab + CHOP | 85 | 77 | 76 |
44 reviews available for prednisolone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cyclophosphamide; Doxorubicin; Etoposide; | 2020 |
Diffuse Large B-cell Lymphoma of Testis: a Case Report and Current Literature Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Humans; Lymphoma, | 2020 |
Asymptomatic gastrosplenic fistula in a patient with marginal zonal lymphoma transformed to diffuse large B cell lymphoma--a case report and review of literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic | 2014 |
Early diagnosis of hepatic intravascular lymphoma: a case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Early Diagnosis | 2014 |
Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Chemorad | 2014 |
Diffuse large B-cell lymphoma with hemolytic crisis developed twenty years after the onset of Evans syndrome.
Topics: Age of Onset; Aged; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemot | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Proto | 2014 |
Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biopsy; Bone Marrow; Bone Marrow Exam | 2016 |
Concomitant non-Hodgkin's lymphoma in colon and liver: report of a rare case and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosphamide; Doxorubicin; Hu | 2015 |
Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Genotype; Humans; Imm | 2015 |
Lymphoproliferative disorders after immunosuppressive therapy for aplastic anemia: a case report and literature review.
Topics: Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Ser | 2009 |
[Primary osseous lymphoma with pathological fracture during therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Rituximab and chemotherapy in diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2009 |
[Management of diffuse large B-cell lymphoma in the rituximab era].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
[Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2009 |
[Intravascular large B-cell lymphoma with massive pulmonary lesions].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
[A case of primary malignant lymphoma of the prostate presenting as urinary retention].
Topics: Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2010 |
Improving therapy for patients with aggressive lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 2011 |
[Intravascular large B-cell lymphoma: an important cause of fever of unknown origin].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2011 |
[Neurological disturbances caused by intravascular lymphomatosis].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; | 2011 |
[Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2011 |
Primary lymphoma of the uterus and cervix: two case reports and review of the literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2011 |
Diffuse large B-cell lymphoma arising primarily at the stoma after bladder reconstruction using ileal conduit.
Topics: Aged; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2012 |
Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CD5 An | 2012 |
Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2004 |
[Case of malignant lymphoma arising from the posterior mediastinum, with pleural effusion].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic | 2004 |
Primary appendiceal lymphoma presenting as perforated acute appendicitis.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Appendi | 2004 |
State-of-the-art therapeutics: diffuse large B-cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Res | 2005 |
What to do when you suspect gastrointestinal lymphoma: a pathologist's perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Non-Hodgkin's lymphoma presenting as an endobronchial tumor: report of eight cases and literature review.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
[Primary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Hu | 1994 |
[Primary non-Hodgkin lymphoma of the prostate: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dau | 1993 |
Case report: primary CD30 (Ki-1)-positive anaplastic large cell lymphoma of the duodenum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Duodenal Neoplasms; H | 1996 |
Malignant lymphoma of the uterine cervix: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Diagnosis, Differe | 1997 |
[Diffuse B-cell lymphoma associated with hemophagocytic syndrome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Epir | 1998 |
Trigeminal neuralgia caused by the metastasis of malignant lymphoma to the trigeminal nerve: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cranial Nerve Neopl | 1998 |
[Renal malignant lymphoma: report of a patient surviving 17 months without recurrence and review of 43 Japanese cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administra | 1998 |
Aggressive bowel lymphoma in a patient with intestinal lymphangiectasia and widespread viral warts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Susceptibility; Dox | 1998 |
Non-Hodgkin's lymphoma of the thyroid and adrenal glands.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclo | 2000 |
[Primary lymphoma of the vagina].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnostic Imaging; Doxorubi | 2001 |
[Ileal perforation due to cytomegalovirus enteritis under chemotherapy for malignant lymphoma. Report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; | 2001 |
The role of mitoxantrone in non-Hodgkin's lymphoma.
Topics: Age Factors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2002 |
Brief chemotherapy, involved field radiation therapy, and central nervous system prophylaxis for paranasal sinus lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System | 1992 |
[A primary malignant lymphoma of the appendix].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combined Modality Therapy; Cy | 1990 |
54 trials available for prednisolone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2023 |
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving S
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2023 |
The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2019 |
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2018 |
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2019 |
The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Line, Tumor | 2019 |
Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycyti | 2019 |
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Long-term results of the R-CEOP90 in the treatment of young patients with chemotherapy-naïve diffuse large B cell lymphoma: a phase II study.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradioth | 2014 |
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placeb
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; | 2016 |
Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; China; Cyclophosphamide; Disease- | 2016 |
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cognition; Cognitive Dysfunction; | 2016 |
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2016 |
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Topics: Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2010 |
[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2009 |
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2010 |
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2010 |
Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Transport | 2011 |
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-De | 2011 |
Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2012 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2012 |
Bullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blister; Cyclophosphamide; Doxorubicin; E | 2012 |
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2003 |
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2003 |
Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2005 |
[Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2005 |
Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2007 |
A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2007 |
Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2008 |
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubi | 2008 |
Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as | 1983 |
[Results of a cooperative clinical study of leumase].
Topics: Adolescent; Adult; Aged; Asparaginase; Child; Child, Preschool; Clinical Trials as Topic; Drug Thera | 1980 |
Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Ch | 1994 |
MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschoo | 1993 |
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etop | 1996 |
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 1997 |
Investigation of the molecular changes during chemotherapy in non-Hodgkin's lymphoma.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophos | 1998 |
[Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
Topics: Adolescent; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 1998 |
A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distr | 2000 |
Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; D | 2001 |
CVP-remission-maintenance in stage I or II non-Hodgkin's lymphomas: preliminary results of a randomized study.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Fema | 1979 |
MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Cooperative Study Group (IMCSGL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
265 other studies available for prednisolone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; beta Catenin; Case-Control Studies; | 2021 |
Long-term clinical course of immunotactoid glomerulopathy complicated with diffuse large B-cell lymphoma.
Topics: Aged; Cyclophosphamide; Doxorubicin; Female; Glomerulonephritis; Humans; Lymphoma, Large B-Cell, Dif | 2022 |
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutrop | 2022 |
Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Fluoro | 2021 |
"Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes From a Developing Country".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Developing Countries; Doxoru | 2022 |
The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
Topics: Adult; Aged; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Femal | 2022 |
[Retroperitoneal Malignant Lymphoma: A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 2023 |
[A Case of Peritoneal Lymphomatosis Diagnosed by Single-Port Laparoscopic Biopsy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Female; | 2022 |
[Large-vessel vasculitis developed after use of long-acting granulocyte colony-stimulating factor in a patient with diffuse large B-cell lymphoma].
Topics: Aged; Fever; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Large B-Cell, Diffuse; Male; P | 2023 |
Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S | 2020 |
Speckle tracking echocardiography in the early detection and prediction of anthracycline cardiotoxicity in diffuse large B-cell lymphoma treated with (R)-CHOP regimen.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cyclophosphamide; Do | 2020 |
Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Borrelia burgdorferi; Brain Neoplasms; Ceftriaxone; | 2020 |
Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse-a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophospha | 2020 |
Gastric emphysema in chemosensitive gastric diffuse large B cell lymphoma.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Emphy | 2020 |
A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Chromosomes, Human, Pai | 2020 |
Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Immunological; Ant | 2021 |
Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2021 |
[Doxorubicin Hydrochloride Liposome-Based CHOP Regimen in the Initial Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2021 |
Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2017 |
Primary dural diffuse large B cell lymphoma mimicking parafalcine meningioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2017 |
Safe use of infliximab for the treatment of severe perianal Crohn's disease after diagnosis and treatment of lymphoma.
Topics: Adult; Anti-Inflammatory Agents; Crohn Disease; Gastrointestinal Agents; Humans; Infliximab; Lymphom | 2018 |
Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2018 |
A case of duodenal malignant lymphoma presenting as acute pancreatitis: systemic lupus erythematosus and immunosuppressive therapy as risk factors.
Topics: Acute Disease; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2018 |
Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2019 |
Cardiac involvement of malignant lymphoma presenting intra-ventricular-wall nodules.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Art | 2019 |
Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B | 2019 |
Widespread primary cutaneous diffuse large B-cell lymphoma, leg type, with nasal involvement.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Leg Ulcer; Lymphoma, Large B-Cell, Diffuse; Male; | 2019 |
[A case of secondary central nervous system lymphoma presenting marked hypoglycorrhachia].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2019 |
Successful Intensive Care Treatment of Severe Lactic Acidosis and Tumor Lysis Syndrome Related to Intravascular Lymphoma.
Topics: Acidosis; Antineoplastic Combined Chemotherapy Protocols; Critical Care; Cyclophosphamide; Doxorubic | 2020 |
Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Doxorubicin; Humans; | 2021 |
Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2013 |
Ewing sarcoma arising after treatment of diffuse large B-cell lymphoma.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormona | 2013 |
Primary hepatic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2014 |
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2013 |
Secondary neurolymphomatosis detected by whole-body diffusion-weighted magnetic resonance imaging: a case report.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2013 |
Breast lymphoma combined with postoperative acute hematopoietic disorder in an immediate breast reconstruction patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Carcinoma, | 2014 |
The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2014 |
What determines therapeutic choices for elderly patients with DLBCL? Clinical findings of a multicenter study in Portugal.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
[Treatment approaches for diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2014 |
Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Primary diffuse large B-cell lymphoma of the testis relapsing in the right atrium.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2015 |
Bone lymphoma revealed by cruralgia during pregnancy: a case report.
Topics: Abortion, Therapeutic; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2014 |
Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2015 |
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Topics: Aneuploidy; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Combined Chem | 2015 |
Intravascular Large B-Cell Lymphoma Complicated by Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that was Successfully Treated with Rituximab-Containing Chemotherapy.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2015 |
Diffuse large B cell lymphoma of the cranial vault: two case reports.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2015 |
Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease- | 2015 |
Laryngeal Lymphoma: Before and After Chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bronchoscopy; Cyclophosphamide; Drug Therapy, Combination; | 2014 |
Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
Subcutaneous Dissemination from an Orbital Diffuse Large B Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2015 |
Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2016 |
How Should We Treat Early Post-Transplant Lymphoproliferative Disease After Heart Transplantation?
Topics: Adult; Colostomy; Cyclosporine; Drug Monitoring; Epstein-Barr Virus Infections; Everolimus; Female; | 2015 |
Two Cases of Intravascular Lymphoma Diagnosed by Gastrointestinal Endoscopic Biopsy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Duodenum; End | 2015 |
Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hu | 2015 |
An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Bone regeneration after chemotherapy for vault lymphoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Regeneration; Cycl | 2016 |
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cyclophosphamide; Doxorubicin; Female; Genes, myc; Human | 2016 |
Polymyositis following autologous haematopoietic stem cell transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p2 | 2016 |
Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; | 2016 |
Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2016 |
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA Mutational Analysis; Dox | 2008 |
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Primary renal lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Kidney Neopla | 2008 |
Primary non-Hodgkin's lymphoma of the uterus, cervix and parametrium treated by combined immunochemotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2008 |
Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2008 |
[HIV-related multiple non-Hodgkin lymphomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclophospham | 2008 |
Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2009 |
Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined C | 2009 |
[Case of primary malignant lymphoma of the liver treated by R-CHOP therapy].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2009 |
[Mediastinal large B-cell lymphoma associated with systemic sclerosis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2009 |
Hematology: germinal center or nongerminal center DLBCL?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Germinal Center; Huma | 2009 |
Primary mediastinal large B-cell lymphoma.
Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplasti | 2009 |
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
Primary anaplastic large B-cell lymphoma in mandible: Long-term complete remission with R-CHOP regimen and involved field radiotherapy.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2009 |
14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
Topics: 14-3-3 Proteins; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
[Usefulness of FDG-PET/CT for the diagnosis of intravascular large B-cell lymphoma presenting with fever of unknown origin and renal dysfunction].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2010 |
Intravascular large B-cell lymphoma of the skin: typical clinical manifestations and a favourable response to rituximab-containing therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineo | 2009 |
[CD4-positive diffuse large B-cell lymphoma].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD4 Antig | 2009 |
Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Coronary sinus obstruction by primary cardiac lymphoma as a cause of dyspnea due to significant diastolic dysfunction and elevated filling pressures.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2010 |
Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
Macrophage colony-stimulating factor produced by diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2010 |
Multiple-cytokine-producing CD30-positive diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic C | 2010 |
Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2010 |
The 51st annual meeting of the American Society of Hematology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
[Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Diffuse large B-cell lymphoma presenting as pancoast tumor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 2011 |
Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2010 |
High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Primary cutaneous intravascular large B-cell lymphoma treated with combination chemotherapy and complicated by rituximab-induced interstitial lung disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2010 |
Richter's syndrome of the brain and the spinal cord.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2011 |
[Primary neurolymphomatosis of the cervical nerve root].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2010 |
A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2011 |
Concomitant adenocarcinoma and colonic non-Hodgkin's lymphoma in a patient with ulcerative colitis: a case report and molecular analysis.
Topics: Adenocarcinoma; B-Lymphocytes; Colitis, Ulcerative; Colonic Neoplasms; DNA Methylation; DNA Mutation | 2010 |
Late relapse in patients with diffuse large B-cell lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2010 |
Rituximab CHOP for successful management of diffuse large B-cell lymphoma of the ovary.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
[Treatment of central nervous system lymphoma following transplantation using monoclonal antibody and ganciclovir].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2010 |
Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Anaplastic Lymphoma Kinase; An | 2011 |
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
Diffuse large B-cell lymphoma with germinal center B-cell phenotype mimicking primary effusion lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
[Repetition of Helicobacter cinaedi infections during chemotherapy for malignant lymphoma].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cefozopran; Cephalospor | 2010 |
Reactive tonsillar enlargement with strong 18F-FDG uptake after chemotherapy for tonsillar diffuse large B-cell lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethas | 2011 |
Herpesviridae viral infections following rituximab combined chemotherapy in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
Primary lymphoma-like lesions of the uterine cervix; sheep in wolves' clothing.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Do | 2011 |
Diffuse large B-cell lymphoma primary of lung.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2011 |
Mastocytosis and diffuse large B-cell lymphoma, an unlikely combination.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
[Non-Hodgkin lymphoma of the mandible--a case report with differential diagnostic considerations].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2011 |
Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineop | 2011 |
Lymphoma in pregnancy initially diagnosed as vaginal intraepithelial neoplasia and lichen planus.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Delivery, Obstetric | 2011 |
Bilateral primary adrenal lymphoma accompanying hypertension.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2012 |
A case of diffuse large B-cell lymphoma of the lung demonstrating diffuse ground-glass shadows.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2011 |
[Clinical analysis of 3 cases with primary splenic diffuse large B-cell lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Cyclophosph | 2011 |
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
Synchronous tumor with diffuse large B-cell lymphoma and ameboma.
Topics: Abdominal Pain; Aged; Amebicides; Antibodies, Monoclonal, Murine-Derived; Antigens, Protozoan; Antin | 2011 |
Richter syndrome in chronic lymphocytic leukaemia manifesting only as tumorous hepatomegaly.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2011 |
Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adrenal Glands; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; | 2012 |
[Case of peritubular capillary dominant intravascular large B-cell lymphoma (PTC dominant IVLBCL) successfully treated with chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Capill | 2011 |
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Chemoprevention; Cyclophosphamide; Doxorubicin; Drug Adminis | 2012 |
Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Prognostic value of platelet count in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Large-cell neuroendocrine cancer of the colon following rituximab-based lymphoma treatment.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2012 |
The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2012 |
Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2012 |
Malignant lymphoma of the vagina successfully treated with rituximab, adryamicin, cyclophosphamide, vincristine sulfate, and prednisolone.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combi | 2012 |
Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; DN | 2012 |
Primary bone lymphoma of the shoulder.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2012 |
FDG-PET guided diagnosis of vaginal intravascular diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capillaries; Cyclophosphamide; Fatal O | 2012 |
[Remission of lymphomatosis cerebri induced by corticosteroid and high-doses intravenous methotrexate].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Humans; Injections, Intravenous; Lymphoma, Large B | 2012 |
A neurological presentation of intravascular B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Early Detection of Cancer; Humans; | 2012 |
[Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
Topics: Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2012 |
Successful treatment of a large primary cardiac lymphoma by surgical resection combined with chemotherapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiac Surgical Procedures; Combined Modality Thera | 2013 |
[Occipital neuralgia (Arnold) as the presenting symptom of diffuse large B-cell non-Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cervical Ver | 2013 |
Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2013 |
Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu | 2013 |
CD5-positive diffuse large B cell lymphoma infiltrating the central nervous system presenting Guillain-Barré-like syndrome after chemotherapy.
Topics: Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD5 Antigens; | 2012 |
[Diffuse large B-cell lymphoma mimicking Wegener's granulomatosis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Do | 2002 |
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2003 |
[A case of primary hepatic lymphoma successfully treated by THP-COP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administra | 2003 |
[Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; | 2003 |
[A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Duodenal Neopla | 2003 |
STEROID THERAPY IN LYMPHOID TUMOURS.
Topics: Betamethasone; Hodgkin Disease; Leukemia; Leukemia, Lymphoid; Lymphoma; Lymphoma, Large B-Cell, Diff | 1963 |
ATRIOVENTRICULAR DISSOCIATION IN A CASE OF RETICULOSARCOMATOSIS AND THE EFFECTS OF STEROID AND CO60 IRRADIATION.
Topics: Cobalt Isotopes; Electrocardiography; Heart Block; Heart Neoplasms; Humans; Leukemia; Lymphoma, Larg | 1964 |
THE MANAGEMENT OF MALIGNANT GRANULOMA.
Topics: Diagnosis; Diagnosis, Differential; Granuloma; Granulomatosis with Polyangiitis; Hodgkin Disease; Hu | 1964 |
[THE RETICULO-ENDOTHELIAL SYSTEM AND LYMPHOSARCOMAS].
Topics: Adolescent; Adrenal Cortex Hormones; Geriatrics; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follic | 1964 |
[LEUKEMIC RETICULO-SARCOMATOSIS FOLLOWING METHYLTESTOSTERONE AND PREDNISOLONE TREATED PANMYELOPATHY AND THROMBOCYTOPENIA].
Topics: Bone Marrow Diseases; Child; Drug Therapy; Leukemia; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non- | 1964 |
DISSEMINATED HISTOPLASMOSIS FOLLOWING LONG-TERM STEROID THERAPY FOR RETICULOSARCOMA.
Topics: Adrenocorticotropic Hormone; Amphotericin B; Blood Transfusion; Bone Marrow Examination; Drug Therap | 1965 |
Favorable response to treatment of a child with T-cell-rich large B-cell lymphoma presenting with liver failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Humans; Liver; | 2003 |
Non-Hodgkin's lymphoma presenting as a giant chest wall mass.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Hemophagocytic syndrome in ileum-origin B-cell lymphoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Cardiac lymphoma successfully treated with high dose chemotherapy followed by autologous haematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chest Pa | 2003 |
[Primary malignant lymphoma arising from the nipple and areolar area of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 2003 |
[Testicular malignant lymphoma: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2003 |
Urinary immunocytology for primary bladder B cell lymphoma.
Topics: Aged; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocy | 2004 |
Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2004 |
Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; Cycloph | 2004 |
A case of intravascular lymphoma with increased regional cerebral blood flow in I-123 IMP single-photon emission CT.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cerebral Infarction; C | 2004 |
Primary mediastinal large B-cell lymphoma: a single-institution clinical study in Japan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2004 |
[Treatment of primary mediastinal large B-cell lymphomas].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleo | 2004 |
Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft.
Topics: Antilymphocyte Serum; Brain Neoplasms; Cytomegalovirus Retinitis; Epstein-Barr Virus Infections; Fem | 2005 |
[A case of pulmonary intravascular lymphoma treated with CHOP chemotherapy plus rituximab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2005 |
Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibodies, Monoclonal; Antibodie | 2005 |
A 61-year-old man with dyspepsia and weight loss.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Long-term clinical outcome after accidental overdose of multiple chemotherapeutic agents.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Overdose; | 2005 |
[A case of malignant lymphoma of the prostate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2005 |
Successful treatment of primary cardiac lymphoma with atrioventricular nodal block.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administra | 2005 |
Non-Hodgkin disease in beta-thalassemia major.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta-Thalassemia; Child; Child, Preschool; Co | 2006 |
[Long-term remission after CHOP therapy in a case of multifocal extranodal diffuse large B-cell lymphoma with t(1 ; 14) (p22 ; q32) and rearrangement of bcl-10].
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Cell C | 2005 |
Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphoc | 2006 |
[A case of primary gastric malignant lymphoma perforated immediately after administration of chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 2006 |
[Effective combined modality therapy for a patient with primary adrenal lymphoma].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Deriv | 2006 |
A malignant fibroleiomyoma of the testis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biopsy, Nee | 2006 |
[The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Unusual case of lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2006 |
[A case of primary pulmonary malignant lymphoma associated with autoimmune hemolytic anemia].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2006 |
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2006 |
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2006 |
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2006 |
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2006 |
Pyoderma gangrenosum complicated with myelodysplastic syndrome followed by rapidly progressing pyothorax-associated lymphoma: a case report.
Topics: Aged; Empyema, Pleural; Herpesvirus 4, Human; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Myelody | 2006 |
Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
18F-Fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Fluorod | 2007 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 2007 |
Successfully-treated mesenteric non-Hodgkin's lymphoma involving hepatic mass--a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Human | 2007 |
Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2007 |
[Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2007 |
Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2007 |
Cyclophosphamide-induced acute respiratory distress syndrome.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2007 |
Mesangiolytic glomerulopathy after radiotherapy and chemotherapy of gastric lymphoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 2007 |
Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Disseminated diffuse large B cell lymphoma of bone on PET scan.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2008 |
Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group).
Topics: Adolescent; Adult; Aged; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Femal | 1980 |
The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosp | 1994 |
[Non-Hodgkin's lymphoma of the bone, with reference to MRI findings following treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Cisplatin; Cycloph | 1993 |
Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1993 |
Synchronous primary hepatic lymphoma and epidermoid lung carcinoma treated with chemotherapy and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1995 |
[Malignant lymphoma of the prostate--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 1993 |
Primary cerebral lymphoma: an argument for the use of adjunctive systemic chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 1993 |
Reversible renal impairment during leukocytosis induced by G-CSF in non-Hodgkin's lymphoma.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 1996 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
Ocular lymphoma in a patient with chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality Therapy; Eye Neo | 1996 |
Diffuse histiocytic lymphoma treated with chemotherapy and radiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1996 |
[A case of gastric malignant lymphoma with perforation during chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosphamide; Doxorubicin; Hu | 1997 |
[Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul | 1997 |
Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1997 |
[A case of malignant lymphoma after renal transplantation].
Topics: Adult; Azathioprine; Brain Neoplasms; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Immuno | 1997 |
[Autologous peripheral blood stem cell transplantation for CHOP-resistant mediastinal diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dr | 1997 |
[Cure by THP-COP therapy in patients with perforated T-cell type malignant lymphoma of the jejunum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
Localized muscle wasting as an initial symptom of skeletal muscle lymphoma.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Diagnosis, Differential; Humans; I | 1998 |
A case of primary non-Hodgkin's lymphoma of the uterine cervix treated by combination chemotherapy (THP-COP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cervix Uteri; Cyclophosphamide; Doxorubicin; Female; | 1998 |
Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etop | 1998 |
Persistent polyclonal lymphocytosis (PPLB)
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberr | 1999 |
[A case of malignant lymphoma of the testis: characterization with ultrasonography and magnetic resonance imaging].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 1999 |
Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fa | 2000 |
[Beneficial effects of CHOP therapy in a case of intravascular large B-cell lymphoma diagnosed by skin biopsy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Humans; Lymph | 2000 |
Epstein-Barr virus (EBV)-induced B-cell proliferative disorder after chemotherapy in a patient with hemophagocytic lymphohistiocytosis with associated EBV-induced T-cell proliferation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Blotting, Southern; Brain Neop | 2000 |
The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Ass | 2000 |
Complete cure of malignant lymphoma of the stomach with a huge adrenal lesion achieved by preoperative chemotherapy and surgery: report of a case.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2001 |
Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone | 2001 |
[CHF arising after low dose THP-COP chemotherapy in an elderly patient with malignant lymphoma].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2001 |
T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
Topics: Aged; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2001 |
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2002 |
Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabin | 2002 |
[Plasma exchange and continuous hemodiafiltration as an initial treatment for diffuse large B-cell lymphoma-associated hemophagocytic syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hemodiafiltrati | 2002 |
Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclona | 2002 |
[A case of malignant lymphoma of the stomach in which preoperative chemotherapy provided a complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gastrec | 2002 |
[Granulocytic sarcoma developing in lymph nodes].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemi | 2002 |
Pituitary function in patients receiving intermittent cytotoxic and corticosteroid therapy for malignant lymphoma.
Topics: Adult; Antineoplastic Agents; Circadian Rhythm; Doxorubicin; Drug Therapy, Combination; Female; Hodg | 1976 |
Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations.
Topics: Adult; Bleomycin; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Resistance; Drug Therapy, Com | 1977 |
[Polychemotherapy in non-hodgkin lymphoma with a modified MOPP scheme (author's transl)].
Topics: Adult; Cyclophosphamide; Female; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Dif | 1977 |
Prednimustine (NSC-134087, Leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas.
Topics: Bone Marrow; Chlorambucil; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; M | 1978 |
[A case of mediastinal malignant lymphoma with cardiac tamponade treated effectively with chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cyclophosphamide; Doxorubic | 1992 |
[Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, La | 1992 |
Bilateral primary non-Hodgkin's lymphoma of the adrenal glands with adrenal insufficiency: a case report.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antineoplastic Combined Chemotherapy Protocols | 1992 |
Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclopho | 1991 |
Malignant lymphoma of the testis presenting as primary testicular tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1991 |
Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 1991 |
Diffuse histiocytic lymphoma: the 20-year experience of an Australian teaching hospital.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chlorambucil; Cyclophosphami | 1988 |
[Cytostatic effects on nucleic acid- and protein synthesis of benign and malignant lymphomas].
Topics: Amides; Antineoplastic Agents; Dactinomycin; DNA, Neoplasm; Hodgkin Disease; Humans; Hydralazine; In | 1967 |
[Nucleic acid synthesis and cytostatic drug effect in pathological lymph node cells].
Topics: Aged; Antineoplastic Agents; Dactinomycin; Depression, Chemical; DNA, Neoplasm; Hodgkin Disease; Hum | 1966 |
Echographic evaluation of abdominal tumor regression during antineoplastic treatment.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorub | 1974 |
Malignant tumours following immunosuppression in renal transplantation.
Topics: Adenocarcinoma; Adult; Azathioprine; Brain Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinom | 1973 |
Epstein-Barr viral nuclear antigen (EBNA) in tumor cell imprints of experimental lymphoma of marmosets.
Topics: Animals; Antigens, Viral; Azathioprine; Burkitt Lymphoma; Cell Line; Cell Nucleus; Cell Transformati | 1974 |
Malignant lymphomas in children. A clinico-pathologic retrospective study. II. Non-Hodgkin's lymphomas.
Topics: Adolescent; Bone Marrow Diseases; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Femal | 1974 |
Haemolytic anaemia in malignant lymphoreticuloendothelial diseases.
Topics: Adult; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoantibodies; Bone Marrow Examination; Ce | 1974 |
[Hypercalcemia syndrome in lymphoreticular sarcoma].
Topics: Adult; Diagnosis, Differential; Female; Humans; Hypercalcemia; Hyperparathyroidism; Lymphoma, Large | 1968 |
[Value of determining the uropepsin level in diseases of the blood treated with steroid hormones].
Topics: Anemia, Aplastic; Endopeptidases; Hodgkin Disease; Humans; Leukemia; Lymphoma, Large B-Cell, Diffuse | 1969 |
Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice.
Topics: Animals; Cell Transformation, Neoplastic; Depression, Chemical; Female; Leukemia, Experimental; Leuk | 1970 |
Combination chemotherapy in malignant disease.
Topics: Administration, Oral; Blood Cell Count; Breast Neoplasms; Bronchial Neoplasms; Child, Preschool; Fem | 1971 |
High-dose corticoid therapy in Hodgkin's disease and other lymphomas.
Topics: Adolescent; Adult; Aged; Cortisone; Diabetes Mellitus; Female; Gastrointestinal Diseases; Hodgkin Di | 1967 |
Cytocidal effect of dimethyl sulfoxide on normal and leukemic lymphocytes.
Topics: Animals; Antineoplastic Agents; Cell Division; Dimethyl Sulfoxide; Hot Temperature; Humans; In Vitro | 1967 |